

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):








- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 215/26, 491/04, A61K 31/47	A1	(11) International Publication Number: WO 99/31067 (43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/US98/26292 (22) International Filing Date: 11 December 1998 (11.12.98) (30) Priority Data: 08/989,576 12 December 1997 (12.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/989,576 (CIP) Filed on 12 December 1997 (12.12.97) (71) Applicant (for all designated States except US): RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US/US]; Old Queens Building, Somerset and George Streets, New Brunswick, NJ 09803 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LAVOIE, Edmond, J. [US/US]; 3 Guilford Court, Princeton Junction, NJ 08550 (US). MAKHEY, Darshan, B. [IN/US]; 10928 Richards Court, Lenexa, KS 66210 (US). ZHAO, Baoping [CA/US]; 156B Cedar Lane, Highland Park, NJ 08904 (US). LIU, Leroy, Fong [US/US]; 5 Fairacres Drive, Bridgewater, NJ 08807 (US).	(74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: HETEROCYCLIC CYTOTOXIC AGENTS (57) Abstract <p>The invention provides compounds of formula (I) wherein R₁-R₈ and X and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I), and therapeutic methods for treating cancer using compounds of formula (I).</p> <div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>4</p> </div> <div style="text-align: center;">  <p>5</p> </div> <div style="text-align: center;">  <p>6</p> </div> <div style="text-align: center;">  <p>7</p> </div> <div style="text-align: center;">  <p>27</p> </div> <div style="text-align: center;">  <p>28</p> </div> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HETEROCYCLIC CYTOTOXIC AGENTS

5 Government Funding

The invention described herein was made with government support under grant CA 39662 awarded by the National Cancer Institute. The United States Government has certain rights in the invention.

Background of the Invention

10 DNA-topoisomerases are enzymes which are present in the nuclei of cells where they catalyze the breaking and rejoining of DNA strands, which control the topological state of DNA. Recent studies also suggest that topoisomerases are also involved in regulating template supercoiling during RNA transcription. There are two major classes of mammalian topoisomerases. DNA-
15 topoisomerase-I catalyzes changes in the topological state of duplex DNA by performing transient single-strand breakage-union cycles. In contrast, mammalian topoisomerase II alters the topology of DNA by causing a transient enzyme bridged double-strand break, followed by strand passing and resealing. Mammalian topoisomerase II has been further classified as Type II α and Type II
20 β . The antitumor activity associated with agents which are topoisomerase poisons is associated with their ability to stabilize the enzyme-DNA cleavable complex. This drug-induced stabilization of the enzyme-DNA cleavable complex effectively converts the enzyme into a cellular poison.

Several antitumor agents in clinical use have potent activity as
25 mammalian topoisomerase II poisons. These include adriamycin, actinomycin D, daunomycin, VP-16, and VM-26 (teniposide or epipodophyllotoxin). In contrast to the number of clinical and experimental drugs which act as topoisomerase II poisons, there are currently only a limited number of agents which have been identified as topoisomerase I poisons. Camptothecin and its
30 structurally-related analogs are among the most extensively studied topoisomerase I poisons. Recently, bi- and terbenzimidazoles (Chen et al., *Cancer Res.* 1993, 53, 1332-1335; Sun et al., *J. Med. Chem.* 1995, 38, 3638-3644; Kim et al., *J. Med. Chem.* 1996, 39, 992-998), certain benzo[c]phenanthridine and protoberberine alkaloids and their synthetic analogs

(Makhey et al., *Med. Chem. Res.* **1995**, *5*, 1-12; Janin et al., *J. Med. Chem.* **1975**, *18*, 708-713; Makhey et al., *Bioorg. & Med. Chem.* **1996**, *4*, 781-791), as well as the fungal metabolites, bulgarein (Fujii et al., *J. Biol. Chem.* **1993**, *268*, 13160-13165) and saintopin (Yamashita et al., *Biochemistry* **1991**, *30*, 5838-5845) and
5 indolocarbazoles (Yamashita et al., *Biochemistry* **1992**, *31*, 12069-12075) have been identified as topoisomerase I poisons.

The exceptional topoisomerase poisoning observed with coralyne, nitidine, 5,6-dihydro-8-desmethylcoralyne and related analogs prompted several recent studies on those structural features which are associated with their ability
10 to act specifically as poisons of topoisomerase I or topoisomerase II (Gatto et al., *Cancer Res.* **1996**, *56*, 2795-2800; Wang et al., *Chem. Res. Toxicol.* **1996**, *9*, 75-83; Wang et al., *Chem. Res. Toxicol.*, **1993**, *6*, 813-818). A common feature associated with all three of these agents is the presence of a 3-phenylisoquinolinium moiety within their structure.


15 Despite the observation that several of these compounds had similar potency to camptothecin as a topoisomerase I poison or similar potency to VM-26 as a topoisomerase II poison, they possessed only modest cytotoxic activity. The absence of a more direct correlation with their potency as topoisomerase poisons was attributed, in part, to the likelihood that these agents are not likely to
20 be absorbed as effectively into cells as either camptothecin or VM-26. The presence of the quaternary ammonium group most likely impedes cellular uptake. It has been speculated that agents such as coralyne and nitidine may need to undergo hydrolysis to permit effective transport, with subsequent dehydration or cyclodehydration to reform the quaternary ammonium parent
25 compound. This may explain the relatively poor antitumor activity observed *in vivo* with agents such as coralyne or nitidine.

Presently, a need exists for novel anti-cancer agents, for anti-cancer agents that exhibit improved activity, and for anti-cancer agents that exhibit fewer side-effects or improved selectivity compared to existing agents.

30 Summary of the Invention

The present invention provides compounds that show inhibitory activity against topoisomerase I and/or topoisomerase II, and compounds that are effective cytotoxic agents against cancer cells, including drug-resistant cancer

cells. Accordingly, the invention provides a compound of the invention which is a compound of formula I:



(I)

wherein

- 5 R_1 , R_2 and R_3 are each individually hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_1 and R_2 taken together are methylenedioxy and R_3 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_2 and R_3 taken together are methylenedioxy and R_1 is hydrogen, $(C_1-$
- 10 $C_6)$ alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo;
- R_4 is oxy, (C_1-C_6) alkyl, or is absent;
- R_5 is hydrogen, hydroxy, or (C_1-C_6) alkyl;
- R_6 , R_7 and R_8 are each individually hydrogen, (C_1-C_6) alkyl, $(C_3-$
- 15 $C_6)$ cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_6 and R_7 taken together are methylenedioxy and R_8 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_7 and R_8 taken together are methylenedioxy and R_6 is hydrogen, $(C_1-$
- 20 $C_6)$ alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $C(=O)R_k$, $COOR_k$, OR_m , or halo;
- each bond represented by ----- is individually present or absent;
- X is $C(R_a)(R_b)$ or NR_c ;
- Y is $C(R_d)(R_e)$ or NR_f ;
- if present, R_a and R_b are each independently hydrogen or (C_1-C_6) alkyl if
- 25 the bond between the 11- and 12-positions represented by ----- is absent; or R_a is

hydrogen or (C₁-C₆)alkyl and R_b is absent if the bond between the 11- and 12-positions represented by ----- is present;

- if present, R_c and R_f are each independently hydrogen or (C₁-C₆)alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_c and R_f are each independently (C₁-C₆)alkyl or absent if the bond between the 11- and 12-positions represented by ----- is present;

- if present, R_d and R_e are each independently hydrogen or (C₁-C₆)alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_d is hydrogen or (C₁-C₆)alkyl and R_e is absent if the bond between the 11- and 12-positions represented by ----- is present;

- each R_g and R_h is independently hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkanoyl, aryl, aryl(C₁-C₆)alkyl, aryloxy, or aryl(C₁-C₆)alkoxy; or R_g and R_h together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, or thiomorpholino;

- each R_k is independently hydrogen, or (C₁-C₆)alkyl; and
each R_m is independently (C₁-C₆)alkanoyl, aryl, or aryl(C₁-C₆)alkyl;
wherein any (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, or (C₁-C₆)alkoxy of R¹, R², R³, R⁶, R⁷, R⁸, or R_k is optionally substituted on carbon with 1, 2, or 3 substituents independently selected from hydroxy, halo, NR_nR_p, (C₃-

- C₆)cycloalkyl, or (C₁-C₆)alkoxy; wherein each R_n and R_p is independently hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, or (C₁-C₆)alkanoyl; or R_n and R_p together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, or thiomorpholino;

- wherein any aryl is optionally be substituted with 1, 2, or 3 substituents independently selected from hydroxy, halo, nitro, trifluoromethyl, trifluoromethoxy, carboxy, amino, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, and (C₁-C₆)alkoxy;

- provided that at least one of R₂ and R₈ is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro; or at least one of R₂ and R₈ forms part of a methylenedioxy; and

- provided that R₁-R₃ and R₆-R₈ are not all hydrogen;
or a pharmaceutically acceptable salt thereof.

The invention also provides a pharmaceutical composition comprising a effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.

The invention also provides a method of inhibiting cancer cell growth, comprising administering to a mammal afflicted with cancer, an amount of a compound of formula (I), effective to inhibit the growth of said cancer cells.

The invention also provides a method comprising inhibiting cancer cell growth by contacting said cancer cell *in vitro* or *in vivo* with an amount of a compound of claim 1, effective to inhibit the growth of said cancer cell.

The invention also provides a compound of formula I for use in medical therapy (preferably for use in treating cancer, e.g. solid tumors), as well as the use of a compound of formula I for the manufacture of a medicament useful for the treatment of cancer, e.g. solid tumors.

The invention also provides processes and novel intermediates disclosed herein which are useful for preparing compounds of the invention. Some of the compounds of formula I are useful to prepare other compounds of formula I.

Brief Description of the Figures

FIG. 1 shows the structure of representative compounds of the invention(6, 7, 27, 28) and other compounds (4 and 5).

FIG. 2 Illustrates the synthesis of compounds of the invention.

FIG. 3 Illustrates the synthesis of compounds of the invention.

FIG. 4 Illustrates the synthesis of intermediate compound 9.

FIG. 5 Illustrates the synthesis of intermediate compound 22.

FIG. 6 Illustrates the synthesis of compounds of the invention wherein X is CR_a and Y is CR_d .

FIG. 7 Illustrates the synthesis of compounds of the invention wherein X is CR_a , Y is CR_d , and R_z is alkyl.

Detailed Description

The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such

as "isopropyl" being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.

It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine topoisomerase poisoning activity or cytotoxicity using the standard tests described herein, or using other similar tests which are well known in the art.

Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents

Specifically, (C₁-C₆)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C₃-C₆)cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; (C₁-C₆)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (C₁-C₆)alkanoyl can be acetyl, propanoyl, butanoyl, pentanoyl, or hexanoyl; and aryl can be phenyl, indenyl, or naphthyl;.

Specifically, R₂ or R₇ can be hydroxy, methoxy, benzyloxy, amino, hydroxymethyl, aminomethyl, aminocarbonyl, methoxycarbonyl, trifluoromethyl, 3-aminopropoxycarbonyl, or 2-hydroxyethyl.

Specifically, R₃ can be hydrogen.

Specifically, R₄ can be absent; or R₄ can be (C₁-C₆)alkyl.

Specifically, R₅ can be methyl or hydrogen.

A specific group of compounds are compounds of formula I wherein R₁, R₂ and R₃ are each individually hydrogen, or (C₁-C₆)alkoxy; or R₁ and R₂ taken

together are methylenedioxy (-OCH₂O-) and R₃ is hydrogen or (C₁-C₆)alkoxy; or a pharmaceutically acceptable salt thereof.

- Another specific group of compounds are compounds of formula I
- wherein: R₁, R₂ and R₃ are each individually hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, NR_gR_h, COOR_k, OR_m, or halo; or
- 5 R₁ and R₂ taken together are methylenedioxy and R₃ is hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, NR_gR_h, COOR_k, OR_m, or halo; or R₂ and R₃ taken together are methylenedioxy and R₁ is hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, NR_gR_h, COOR_k, OR_m, or halo;
- 10 OR_m, or halo; R₄ is oxy, (C₁-C₆)alkyl, or is absent; R₅ is hydrogen, hydroxy, or (C₁-C₆)alkyl; R₆, R₇ and R₈ are each individually hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, NR_gR_h, COOR_k, OR_m, or halo; or R₆ and R₇ taken together are methylenedioxy and R₈ is hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, NR_gR_h, COOR_k, OR_m, or halo;
- 15 or R₇ and R₈ taken together are methylenedioxy and R₆ is hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, NR_gR_h, COOR_k, OR_m, or halo; each bond represented by ---- is individually present or absent; X is C(R_a)(R_b) or NR_c; Y is C(R_d)(R_e) or NR_f; if present, R_a and R_b are each independently hydrogen or (C₁-C₆)alkyl if the bond between the 11- and
- 20 12-positions represented by ---- is absent; or R_a is hydrogen or (C₁-C₆)alkyl and R_b is absent if the bond between the 11- and 12-positions represented by ---- is present; if present, R_c and R_f are each independently hydrogen or (C₁-C₆)alkyl if the bond between the 11- and 12-positions represented by ---- is absent; or R_c and R_f are each independently (C₁-C₆)alkyl or absent if the bond between the 11- and 12-positions represented by ---- is present; if present, R_d and R_e are each independently hydrogen or (C₁-C₆)alkyl if the bond between the 11- and 12-positions represented by ---- is absent; or R_d is hydrogen or (C₁-C₆)alkyl and R_e is absent if the bond between the 11- and 12-positions represented by ---- is present; each R_g and R_h is independently hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkanoyl, aryl, aryl(C₁-C₆)alkyl, aryloxy,
- 30 or aryl(C₁-C₆)alkoxy; or R_g and R_h together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, or thiomorpholino; each R_k is independently hydrogen, or (C₁-C₆)alkyl; and each R_m is independently (C₁-

C₆)alkanoyl, aryl, or aryl(C₁-C₆)alkyl; provided that at least one of R₂ and R₈ is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro; or at least one of R₂ and R₈ forms part of a methylenedioxy; and provided that R₁-R₃ and R₆-R₈ are not all hydrogen; or a pharmaceutically acceptable salt thereof.

- 5 Another specific group of compounds are compounds of formula I wherein R₇ or R₈ is (C₁-C₆)alkoxy; or R₇ and R₈ taken together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

- Another specific group of compounds are compounds of formula I wherein R₇ and R₈ taken together are methylenedioxy; or a pharmaceutically
10 acceptable salt thereof.

 Another specific group of compounds are compounds of formula I wherein the bonds represented by ----- are both present; or a pharmaceutically acceptable salt thereof.

- Another specific group of compounds are compounds of formula I
15 wherein the bond between the 5- and the 6-positions that is represented by ----- is absent; or a pharmaceutically acceptable salt thereof.


 Another specific group of compounds are compounds of formula I wherein the bond between the 11- and the 12-positions that is represented by ---- - is absent; or a pharmaceutically acceptable salt thereof.

- 20 Another specific group of compounds are compounds of formula I wherein the bonds represented by ----- are both absent; or a pharmaceutically acceptable salt thereof.

- Another specific group of compounds are compounds of formula I wherein X is NR_e; Y is NR_f; and R_e and R_f are each hydrogen or (C₁-C₆)alkyl if
25 the bond between the 11- and 12-positions represented by ----- is absent; or R_e and R_f are each (C₁-C₆)alkyl or absent if the bond between the 11- and 12-positions represented by ----- is present; or a pharmaceutically acceptable salt thereof.

- Another specific group of compounds of formula I, are compounds of
30 formula III:


9



wherein

- R_1 - R_8 are defined as hereinabove for the corresponding radical in a compound of formula I; each bond represented by ----- is individually present or absent; and R_f is hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_f is (C_1-C_6) alkyl or absent if the bond between the 11- and 12-positions represented by ----- is present; or a pharmaceutically acceptable salt thereof.

Another specific group of compounds of formula I, are compounds of formula IV:



10

- wherein R_1 - R_8 are defined as hereinabove for the corresponding radical in a compound of formula I; each bond represented by ----- is individually present or absent; and R_c is hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_c is (C_1-C_6) alkyl or absent if the bond between the 11- and 12-positions represented by ----- is present; or a pharmaceutically acceptable salt thereof.

Another specific group of compounds are compounds of formula I wherein R_1 is (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or R_1 and R_2 taken together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

Another specific group of compounds are compounds of formula I
5 wherein R_2 is (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or a pharmaceutically acceptable salt thereof.


Another specific group of compounds are compounds of formula I wherein R_3 is (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or R_2 and R_3 taken together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

10 Another specific group of compounds are compounds of formula I wherein R_8 is (C_1-C_6) alkoxy, nitro, hydroxy or halo; or R_7 and R_8 taken together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

Another specific group of compounds are compounds of formula I wherein R_7 is (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or a pharmaceutically
15 acceptable salt thereof.

Another specific group of compounds are compounds of formula I wherein R_6 is (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or R_6 and R_7 taken together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

A preferred compound of the invention is a compound of formula I:



20 wherein

R_1 , R_2 and R_3 are each individually hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or R_1 and R_2 taken together are methylenedioxy $(-OCH_2O-)$ and R_3 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or R_2 and R_3 taken

together are methylenedioxy (-OCH₂O-) and R₁ is hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy or halo;

R₄ is oxy (forming an amine oxide), (C₁-C₆)alkyl, or is absent;

R₅ is hydrogen, hydroxy, or (C₁-C₆)alkyl;

- 5 R₆, R₇ and R₈ are each individually hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, or halo; or R₆ and R₇ taken together are methylenedioxy (-OCH₂O-) and R₈ is hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy, or halo; or R₇ and R₈ taken together are methylenedioxy (-OCH₂O-) and R₆ is hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkoxy, nitro, hydroxy or halo;
- 10

each bond represented by ----- is individually present or absent;

X is C(R_a)(R_b) or NR_c;

Y is C(R_d)(R_e) or NR_f;

if present, R_a and R_b are each independently hydrogen or (C₁-C₆)alkyl if

- 15 the bond between the 11- and 12-positions represented by ----- is absent; or R_a is hydrogen or (C₁-C₆)alkyl and R_b is absent if the bond between the 11- and 12-positions represented by ----- is present;

if present, R_c and R_f are each independently hydrogen or (C₁-C₆)alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_c

- 20 and R_f are each independently (C₁-C₆)alkyl or absent if the bond between the 11- and 12-positions represented by ----- is present; and

if present, R_d and R_e are each independently hydrogen or (C₁-C₆)alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_d is hydrogen or (C₁-C₆)alkyl and R_e is absent if the bond between the 11- and

- 25 12-positions represented by ----- is present;

provided that R₂ and R₃ are not both (C₁-C₆)alkoxy; and


provided that R₁-R₃ and R₆-R₈ are not all hydrogen;

or a pharmaceutically acceptable salt thereof.

Another preferred compound of formula (I) is a compounds of

- 30 formula (V):

12




(V)

wherein

R_1 - R_8 are defined as hereinabove for the corresponding radical in a compound of formula I; each bond represented by ----- is individually present or absent; or a pharmaceutically acceptable salt thereof.

A preferred compound of the invention is 2,3-methylenedioxy-8,9-dimethoxybenzo[i]phenanthridine; or a pharmaceutically acceptable salt thereof.

A compound of formula I can be prepared by reducing the nitro group of a compound of formula II:



(II)

wherein R_1 - R_3 , R_6 - R_8 , X and Y are defined as they are for a compound of formula I, under conditions which give the imine ring closure product.

Conditions suitable for reduction of the nitro group are well known to the art.

For example, the hydrolysis may conveniently be carried out with zinc in acetic acid, under conditions similar to those described in Example 1.

An intermediate useful for preparing a compound of formula I, is a compound of formula II. A compound of formula II (for example compound 17 or 18) can be prepared using procedures similar to those illustrated in Figure 2

and described in the sub-parts of Examples 1 and 3. Treatment of 6,7-dimethoxy- β -tetralone (8) and 6,7-methylenedioxy- β -tetralone (9) with dimethyl formamide and phosphorus tribromide gave the respective 3,4-dihydro-2-bromonaphthaldehyde derivatives in about 70% yield, which were oxidized using DDQ in toluene quantitatively to the respective bromonaphthaldehydes, 10 and 11. Acetals 12 and 13 were obtained in 95% yield by treatment of the respective bromonaphthaldehydes with ethylene glycol in presence of a catalytic amount of *p*-toluenesulfonic acid. A Dean-Stark apparatus was used to remove the water generated during the reaction. Lithium-halogen exchange was performed by treatment of the acetals 12 and 13 with butyllithium and then quenched with trimethylborate. Acidic work-up of the reaction products resulted in the formation of the boronic acid derivatives, 14 and 15 respectively. Palladium (0) catalyzed coupling of compounds 14 and 15 with the *o*-bromonitrobenzene derivative, 16, resulted in the formation of the 2-phenylnaphthalene derivatives, 17 and 18, respectively, in about 80% yield. Reduction and concomitant cyclization of the nitro groups of 17 and 18 resulted in the of the desired benzo[i]phenanthridines, 4 and 6, respectively, in about 70% yield.

A compound of formula II (for example compound 25 or 26) can also be prepared using procedures similar to those illustrated in Figure 3 and described in the sub-parts of Examples 2 and 4. Grignard reactions performed on the respective naphthaldehydes, 10 and 11, with methylmagnesium bromide, followed by oxidation of the alcohols obtained with pyridinium chlorochromate resulted in the formation of the ketones 23 and 24, respectively. These ketones were then directly coupled with the tin compound (22) to give the 2-phenylnaphthalenes 25 and 26, respectively. Reduction and concomitant cyclization of 25 and 26 occurred on treatment with zinc in acetic acid to give the desired 5-methyl substituted benzo[i]phenanthridines 5 and 7, respectively.

Another intermediate useful for preparing compounds of the invention is the β -tetralone 9, which can be prepared as illustrated in Figure 4. 3,4-methylenedioxy-phenylpropionic acid was esterified to give ethyl ester, 19. Treatment of 19 with the anion of dimethyl sulfate resulted in the formation of the β -ketosulfoxide, 20, which cyclized on treatment with trifluoroacetic acid to

the 1-methylthio- β -tetralone, **21**. Reductive desulfurization of **21** gave 6,7-methylenedioxy- β -tetralone, **9**.

Another intermediate useful for preparing compounds of the invention is the compound **22**, which can be prepared as illustrated in Figure 5. Nitration of
5 4-bromo-1,2-dimethoxybenzene gave compound **16**, which was treated with hexamethylditin to give the tin compound **22**.

As illustrated in Figure 6, a compound of formula (I) wherein X is CR_a and Y is CR_d can be prepared using procedures similar to those described herein.

As illustrated in Figure 7, a compound of formula (I) wherein X is CR_a,
10 Y is CR_d, and R₃ is alkyl can be prepared using procedures similar to those described herein.

A compound of formula (I) wherein X and/or Y is nitrogen can be prepared using techniques similar to those described by: M.J.S. Dewar and W.H. Poesche, A New Route to Polycyclic Benzocinnolines, *J. Chem. Soc.*,
15 2201-2203, 1963; R.S.W. Braithwaite and G.K. Robinson, Unsymmetrical Polynuclear Cinnoline Derivatives. Part I. Cyclisation of Some Cyclohexane-1,2-dione 1-Arylhydrazones, *J. Chem. Soc.*, 3671-3676, 1962; J.F. Corbett and P.F. Holt, Polycyclic Cinnoline Derivatives. Part VIII. Cinnolines and their N-oxides and oo'-Diaminobiaryls, *J. Chem. Soc.*, 3695-3699, 1961.

20 The formation of quaternary N-methylated analogs of benzo[i]phenathridines can be accomplished by heating the compound neat in the presence of dimethyl sulfate in a sealed tube as described by A.R. Surrey, *Org. Syn., Coll. Vol.*, 3, 753-756, 1955 in the preparation of Pyrocyanine, see below.

25 In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate,
30 succinate, benzoate, ascorbate, α -ketoglutarate, and α -glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or
5 alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

The compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or
10 parenterally, by intravenous, intramuscular, topical or subcutaneous routes.

Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be
15 incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The
20 percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the
25 following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring
30 may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance,

tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in
5 preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or
10 its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

15 The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form must be sterile, fluid and stable
20 under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the
25 formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for
30 example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, 5 the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to 10 administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the 15 present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the 20 affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

25 Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Useful dosages of the compounds of formula I can be determined by 30 comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

Generally, the concentration of the compound(s) of formula I in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.

5 The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

10 In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.

15 The compound may conveniently be administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.

 Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 μ M, preferably, about 1 to 50 μ M, most preferably, about 2 to about 30 μ M. This
20 may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or
25 by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).

 The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g.,
30 into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

The ability of a compound of the invention to effect topoisomerase I or II mediated DNA cleavage can be determined using pharmacological models that are well known to the art, for example, using a model like Test A described below.

5

Test A. Topoisomerase I and topoisomerase II cleavage assay.

Representative compounds of the invention were evaluated in cleavage assays for the recombinant topoisomerases I and calf thymus topoisomerases I and II. These assays were performed as described by B. Gatto et al. *Cancer Res.*,
10 1996, 56, 2795-2800. Human topoisomerase I was isolated as a recombinant fusion protein using a T7 expression system. DNA topoisomerase II was purified from calf thymus gland as reported by Halligan, B. D.; Edwards, K. A.; Liu, L. F. "Purification and characterization of a type II DNA topoisomerase from bovine calf thymus," *J. Biol. Chem.* 1985, 260, 2475. Plasmid YEpg was
15 purified by the alkali lysis method followed by phenol deproteination and CsCl/ethidium isopycnic centrifugation as described by Maniatis, T.; Fritsch, E. F.; Sambrook, J. *Molecular Cloning, a Laboratory Manual*; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY 1982; pp 149-185. The end-labeling of the plasmid was accomplished by digestion with a restriction enzyme followed by
20 end-filling with Klenow polymerase as previously described by Liu, L. F.; Rowe, T. C.; Yang, L.; Tewey, K. M.; Chen, G. L. "Cleavage of DNA by mammalian topoisomerase II," *J. Biol. Chem.* 1983, 258, 15365.

The cytotoxic effects of a compound of the invention can be determined using pharmacological models that are well known to the art, for example, using
25 a model like Test B described below.

Test B. Cytotoxicity assay.

The cytotoxicity was determined using the MTT-microtiter plate tetrazolinium cytotoxicity assay (MTA) (See Chen A.Y. et al. *Cancer Res.* 1993,
30 53, 1332; Mosmann, T. J., *J. Immunol. Methods* 1983, 65, 55; and Carmichael, J. et al. *Cancer Res.* 1987, 47, 936). The human lymphoblast RPMI 8402 and its camptothecin-resistant variant cell line, CPT-K5 were provided by Dr. Toshiwo Andoh (Aichi Cancer Center Research Institute, Nagoya, Japan) (see Andoh, T.;

Okada, K. "Drug resistance mechanisms of topoisomerase I drugs," *Adv. in Pharmacology* 1994, 29B, 93. The cytotoxicity assay was performed using 96-well microtiter plates. Cells were grown in suspension at 37 °C in 5% CO₂ and maintained by regular passage in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (0.1 mg/mL). For determination of IC₅₀, cells were exposed continuously with varying concentrations of drug and MTT assays were performed at the end of the fourth day.

10 **Table 1.** Pharmacological Activity of Compounds of the Invention

Compound	Topo I-mediated DNA cleavage ^b	Topo II-mediated DNA cleavage ^c	Cytotoxicity IC ₅₀ ^a (μM) Cell Lines	
			RPMI	CPT-K5
4	>1000	>1000	22.9	22.9
5	>1000	>1000	27.5	>27.5 ^d
15 6	100	10	7.5	7.0
7	200	100	10.1	14.4
27	25	>1000	1.3	5.2
28	25	>1000	0.2	0.2
29	100	>1000	15	20
20 30	250	>1000	7.5	7.5
31	50	>1000	3.0	3.0
Nitidine	1	1	0.65	>2.6 ^d
CPT	1	>1000	0.004	>10 ^d
VM-26	>1000	1	0.3	0.5

25

a) IC₅₀ has been calculated after 4 days of continuous drug exposure.

30

b) Topoisomerase I cleavage values are reported as REC, Relative Effective Concentration, i.e., concentrations relative to camptothecin (CPT), whose value is arbitrarily assumed as 1, that are able to produce the same cleavage on the plasmid DNA in the presence of human topoisomerase I.

35

c) Topoisomerase II cleavage values are reported as REC, Relative Effective Concentration, i.e., concentrations relative to VM-26, whose value is arbitrarily assumed as 1, that are able to produce the same cleavage on the plasmid DNA in the presence of calf thymus topoisomerase II. VM-26 (teniposide or epipodophyllotoxin) was obtained from the National Cancer Institute.

d) IC₅₀ value substantially greater than the highest doses assayed

40


Certain compounds of formula I, are potent topoisomerase I poisons. Additionally, compounds of formula I generally possess cytotoxic activity against RPMI 8402 cancer cells and camptothecin resistant CPT-K5 cells.

Accordingly, compounds of formula I may be useful as cytotoxic agents, for the treatment of cancers, in particular, solid mammalian tumors or hematologic malignancies. Additionally, compounds of the invention may be useful as pharmacological tools for the further investigation of topoisomerase function.

- 5 As used herein, the term "solid mammalian tumors" include cancers of the head and neck, lung, mesothelioma, mediastinum, esophagus, stomach, pancreas, hepatobiliary system, small intestine, colon, rectum, anus, kidney, ureter, bladder, prostate, urethra, penis, testis, gynecological organs, ovarian, breast, endocrine system, skin central nervous system; sarcomas of the soft tissue
10 and bone; and melanoma of cutaneous and intraocular origin. The term "hematological malignancies" includes childhood leukemia and lymphomas, Hodgkin's disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia, plasma cell neoplasm and cancers associated with AIDS. The preferred mammalian species for treatment are humans and domesticated
15 animals.

- Compounds 6 and 7 exhibit potent activity as topoisomerase I poisons. This is believed to be due in part to the favorable placement of the methylenedioxy group. Compounds 4 and 5 demonstrate significantly less topoisomerase I poisoning activity. This is believed to be due to the presence of
20 methoxy group at the (R_s) 3-position. Based on this reasoning, it might be expected that compound
28 would also possess diminished topoisomerase I poisoning activity, in view of the fact that there is a methoxy group at the 3-position. Compound 28, however, demonstrates potent topoisomerase poisoning activity.

- 25 This apparent anomaly can be explained by the fact that, if compound 28 (as shown in Figure 1) is flipped vertically by 180 degrees, and then flipped horizontally by 180 degrees, it provides the following structure.



This structure has a methylenedioxy substituent in the positions corresponding to R_7 and R_8 in a compound of formula I. This suggests that benzo[i]phenanthridines having alkoxy substituents at either the 3- or 9-position should retain good topoisomerase poisoning activity, whereas those compounds
5 having alkoxy substituents at both the 3- and 9-position may possess diminished activity. This also suggests that compounds having a nitrogen in the 12-position should retain topoisomerase poisoning activity.

The invention will now be illustrated by the following non-limiting Examples, wherein unless otherwise stated: melting points were determined with
10 a Thomas-Hoover Unimelt capillary melting point apparatus; column chromatography refers to flash chromatography conducted on SiliTech 32-63 μm , (ICN Biomedicals, Eschwege, Ger.) using the solvent systems indicated; infrared spectral data (IR) were obtained on a Perkin-Elmer 1600 Fourier transform spectrophotometer and are reported in cm^{-1} ; proton (^1H NMR) and
15 carbon (^{13}C NMR) nuclear magnetic resonance were recorded on a Varian Gemini-200 Fourier Transform spectrometer; NMR spectra (200 MHz ^1H and 50 MHz ^{13}C) were recorded in the deuterated solvent indicated with chemical shifts reported in δ units downfield from tetramethylsilane (TMS); coupling constants are reported in hertz (Hz); mass spectra were obtained from Washington
20 University Resource for Biomedical and Bio-organic Mass Spectrometry within the Department of Chemistry at Washington University, St. Louis, MO; and combustion analyses were performed by Atlantic Microlabs, Inc., Norcross, GA, and were within $\pm 0.4\%$ of the theoretical value.

Examples

Example 1. 2,3,8,9-Tetramethoxybenzo[i]phenanthridine (4).

5 Compound 17 (100 mg, 0.52 mmol) was dissolved in glacial acetic acid (8 mL) and heated to reflux with zinc dust (200 mg, 3.2 mmol) for 4 hours. The acetic acid was evaporated *in vacuo*, and the residue was extracted with chloroform. The chloroform solution was filtered through a celite bed. The filtrate was washed successively with saturated sodium bicarbonate solution and
10 brine and evaporated to dryness. The residue was purified by chromatography (silica), with hexanes:ethyl acetate (1:1) as the eluent to give the title compound in 54% yield; mp = 267-268 °C; IR (Nujol) 1621, 1513, 1282; ¹H NMR δ 4.04 (3H, s), 4.06 (3H, s), 4.10 (3H, s), 4.13 (3H, s), 7.22 (1H, s), 7.55 (1H, s), 7.74 (1H, s), 7.89 (1H, d, *J* = 8.8), 8.05 (1H, s), 8.18 (1H, d, *J* = 8.8), 9.82 (1H, s); ¹³C
15 NMR δ 56.4, 56.6, 102.0, 102.3, 108.5, 109.9, 118.3, 118.4, 120.7, 120.8, 125.7, 127.5, 130.7, 141.5, 145.9, 150.0, 150.1, 150.9, 151.4; HRMS calcd for C₂₁H₁₉NO₄: 349.1314; found: 349.1321.

The intermediate compound 17 was prepared as follows.

20

a. **2-Bromo-6,7-dimethoxy-1-naphthaldehyde (10).** Dimethylformamide (3.0 g, 41 mmol) was added dropwise to solution of phosphorus tribromide (3.3 mL, 35 mmol) in dry chloroform (50 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h to give pale yellow suspension. A solution of compound 8 (2.0 g, 9.7
25 mmol) in chloroform was added to the yellow suspension and the mixture was heated at reflux for 1 h. The reaction mixture was cooled to 0 °C and saturated aqueous NaHCO₃ solution was added dropwise until no effervescence was obtained. The resulting mixture was extracted with dichloromethane, dried (Na₂SO₄) and evaporated to provide the respective 2-bromo-3,4-dihydro-1-
30 naphthaldehyde derivatives as yellow solids. Each of the 2-bromo-3,4-dihydro-1-naphthaldehyde derivatives were chromatographed on silica gel using a 3:1 mixture of hexanes:ethyl acetate as the eluent to give the 2-bromo-3,4-dihydro-1-naphthaldehydes in an 87% yield. The 2-bromo-3,4-dihydro-1-naphthaldehyde

(2.4 g, 8.1 mmol) and DDQ (2.2 g, 97 mmol) was refluxed in toluene (50 mL) for 15 h. After cooling to room temperature, the mixture was subjected to filtration through a celite bed and the filtrate was evaporated to dryness. The residue obtained was chromatographed on 75 g silica gel using a 3:1 mixture of
5 hexanes:ethyl acetate as eluent to give the 2-bromo-1-naphthaldehyde in a 95% yield; ^1H NMR δ 4.00 (3H, s), 4.05 (3H, s), 7.07 (1H, s), 7.54 (1H, d, $J = 8.5$), 7.79 (1H, d, $J = 8.5$), 8.71 (1H, s), 10.74 (1H, s); ^{13}C NMR δ 56.3, 56.6, 104.2, 107.0, 126.5, 128.8, 129.4, 129.8, 129.9, 134.3, 150.4, 153.1, 195.9; HRMS calcd for $\text{C}_{13}\text{H}_{11}\text{O}_3\text{Br}$: 293.9891; found: 293.9896.

10

b. **2-Bromo-6,7-dimethoxynaphthaldehyde-1-ethylacetal (12).** Compound 10 (540 mg, 1.95 mmol), ethylene glycol (0.7 mL) and *p*-toluenesulfonic acid (10 mg) were dissolved in 30 mL dry toluene. This reaction mixture refluxed under nitrogen in a flask fitted with a Dean-Stark apparatus to remove the water
15 formed during acetal formation. At the end of the reaction (15 h), the solvent from the cooled reaction mixture was evaporated *in vacuo* and the residue obtained was dissolved in 50 mL ethyl acetate. The ethyl acetate solution was washed with a saturated solution of sodium bicarbonate, dried and the solvent was removed to give the crude acetal. Chromatography on silica gel using a
20 3:17 mixture of ethyl acetate:hexanes afforded the pure acetal as a clear viscous liquid in a 95% yield; IR (Nujol) 1660, 1635; ^1H NMR δ 4.02 (3H, s), 4.06 (3H, s), 4.13-4.19 (2H, m), 4.38-4.48 (2H, m), 7.09 (1H, s), 7.54-7.68 (2H, m), 7.72 (1H, s), 7.78 (1H, s); ^{13}C NMR δ 56.2, 56.6, 65.7, 102.8, 104.6, 106.5, 122.9, 128.4, 129.1, 130.5, 131.2, 131.3, 148.0, 148.5; Anal. calcd for $\text{C}_{15}\text{H}_{15}\text{O}_4\text{Br}$: C, 53.11, H, 4.48; Found: C, 52.93, H, 4.51.
25

c. **1-Formyl-6,7-dimethoxynaphth-2-yl boronic acid (14).** Acetal 12 (1.4 mmol) was dissolved in 10 mL anhydrous tetrahydrofuran. This solution was stirred under nitrogen at -78°C . A hexanes solution of *n*-butyllithium (1.2 mL, 2.8 mmol) was added slowly and the reaction mixture was stirred at -78°C for
30 30 min. A pale yellowish brown solution was obtained. To this yellow reaction mixture trimethylborate (0.5 mL, 4.2 mmol) was added and the resulting mixture was stirred at -78°C for 1 h prior to allowing it to come to room temperature. A

5% solution of hydrochloric acid (20 mL) was added to the reaction mixture and stirred for 30 min at room temperature. The tetrahydrofuran was evaporated *in vacuo* and the water layer was extracted with dichloromethane. The combined organic layer was washed once with brine, dried and evaporated to give the boronic acid derivative 14, which was used in the subsequent step without further purification.

d. **2-(3,4-Dimethoxy-6-nitrophenyl)-6,7-dimethoxy-1-naphthaldehyde (17).**

10 In a 3 neck flask compound 16 (876 mg, 3.34 mmol, prepared in sub-part e below) was taken with 430 mg of tetrakis(triphenylphosphine)palladium (0) in 20 mL dimethoxyethane and the resulting solution was stirred at room temperature under nitrogen for 30 min. The solution changed color from brown to yellow. A solution of compound 14 (1.1 mmol) in 5 mL dimethoxyethane
15 was added to the reaction mixture followed by the addition of 5 mL of 2 M sodium carbonate solution. The reaction mixture was refluxed for 18 h. The reaction mixture was allowed to come to room temperature and the reaction mixture was filtered through a celite bed. The filtrate was evaporated to dryness and the residue obtained was column chromatographed on 75 g silica gel using
20 1:9 mixture of ethyl acetate:hexanes. The fourth compound eluting from the column was collected and the combined fractions were evaporated *in vacuo* to give the 2-phenyl-1-naphthaldehyde derivative 17 in 22% yield, based on the acetal; mp = 228-230; IR (Nujol) 1676, 1513, 1259. This compound was used for the synthesis of compound 4 without further characterization.

25

The intermediate compound 16 used in Example 1, sub-part d, was prepared as follows.

e. **3,4-Dimethoxy-6-nitro-bromobenzene (16).** 3,4-

30 Dimethoxybromobenzene (5 g, 23 mmol) was slowly added to a stirred solution of 35 mL concentrated nitric acid and 105 mL glacial acetic acid maintained at 10 °C. The reaction mixture was stirred at 15 °C for 1 h and then diluted with 200 mL ice cold water. The resulting mixture was extracted thrice with 200 mL

portions of ether. The combined organic phase was dried and evaporated *in vacuo*. The crude product was recrystallized from ethanol to give bright yellow needle shaped crystals of compound **16** in 92% yield; mp = 122-124 °C; IR (Nujol) 1510, 1312; ¹H NMR δ 3.94 (3H, s), 3.97 (3H, s), 7.12 (1H, s), 7.57 (1H, s); ¹³C NMR δ 56.9, 57.2, 108.0, 109.5, 117.0, 148.7, 153.3; Anal. calcd for C₈H₈NO₄Br: C, 36.72, H, 3.14, N, 5.30; Found: C, 36.70, H, 3.13, N, 5.29.

Example 2. 5-Methyl-2,3,8,9-tetramethoxybenzo[i]phenanthridine (5).

Using a procedure similar to that described in Example 1, except replacing the compound **17** used therein with compound **25**, the title compound was prepared in 60% yield; mp = 255-257 °C; IR (Nujol) 1620, 1513, 1209; ¹H NMR δ 3.42 (3H, s), 4.08 (6H, s), 4.13 (6H, s), 7.33 (1H, s), 7.52 (1H, s), 7.82 (1H, s), 7.98 (1H, d, *J* = 8.8), 8.32 (1H, s), 8.35 (1H, d, *J* = 8.8); ¹³C NMR δ 31.6, 56.4, 56.5, 56.6, 102.1, 108.7, 108.8, 108.9, 118.6, 119.0, 122.2, 126.5, 129.0, 130.9, 132.6, 140.4, 149.1, 149.6, 149.7, 151.7, 154.9; HRMS calcd for C₂₂H₂₁NO₄: 363.1470; found: 363.1471.

The intermediate compound **25** was prepared as follows.

20

a. **1-Aceto-2-bromo-6,7-dimethoxynaphthalene (23).** A 1.4 M solution of methylmagnesium bromide in tetrahydrofuran (16.8 mL, 16.8 mmol) was added to a solution of naphthaldehyde **10** in 20 mL dry tetrahydrofuran at 0 °C under nitrogen. The reaction mixture was stirred for 1 h at 0 °C. The reaction was quenched by dropwise addition of 100 mL water followed by rapid addition of 50 mL 0.1 N hydrochloric acid. The reaction mixture was extracted with ethyl acetate, dried and the solvent was evaporated *in vacuo* to give an oily residue. The oil was triturated with chloroform to give the alcohol as a white needle shaped crystalline solid in 95% yield. Pyridinium chlorochromate (857 mg, 3.98 mmol) was suspended in 10 mL dry dichloromethane. The alcohols (2.49 mmol) was added to this suspension and the resulting mixture was stirred under nitrogen at room temperature for 6 h. Ether (100 mL) was added to the reaction mixture and the suspension obtained was filtered through a celite bed. The filtrate was

evaporated to dryness and the residue obtained was chromatographed on 75 g silica gel using a 1:9 mixture of ethyl acetate:hexanes to give the 1-aceto-2-bromonaphthalene derivatives **23** as fluffy bright white needles in 85% yield; mp = 102-103 °C; IR (Nujol) 1693; ¹H NMR δ 2.70 (3H, s), 3.95 (3H, s), 3.99 (3H, s), 6.84 (1H, s), 7.10 (1H, s), 7.43 (1H, d, *J* = 8.4), 7.56 (1H, d, *J* = 8.4); ¹³C NMR δ 32.4, 56.4, 103.1, 107.2, 113.3, 126.3, 128.2, 128.7, 129.1, 139.0, 150.4, 151.4, 205.5; HRMS calcd for C₁₄H₁₃O₃Br: 308.0048; found: 308.0059.

b. **1-Aceto-2-(3,4-dimethoxy-6-nitrophenyl)-6,7-dimethoxynaphthalene (25).** A mixture containing compound **22** (0.98 mmol), the 1-aceto-2-bromonaphthalene **23** (0.89 mmol), (Ph₃P)₄Pd (106 mg) and copper cyanide (17 mg) was refluxed in 20 mL toluene under nitrogen for 20-24 h. After cooling to room temperature, ethyl acetate (20 mL) was added to the reaction mixture and the organic layer was poured into a separating funnel. The organic layer was washed with 20 mL of distilled water. The two phases were allowed to separate as much as possible and the aqueous layer was discarded. The remaining emulsion was passed through a celite bed. The organic layer was separated from the filtrate and evaporated to dryness. The residue obtained was chromatographed on 75 g silica gel using a 3:2 mixture of hexanes:ethyl acetate to give the 1-aceto-2-(3,4-dimethoxy-6-nitrophenyl)naphthalene derivative **25** in 30% yield; mp = 185-187 °C; IR (Nujol) 1689, 1503, 1260; ¹H NMR δ 2.25 (3H, s), 3.90 (3H, s), 3.98 (3H, s), 4.02 (3H, s), 4.03 (3H, s), 6.76 (1H, s), 7.08 (1H, d, *J* = 8.4), 7.12 (1H, s), 7.18 (1H, s), 7.70 (1H, s), 7.71 (1H, d, *J* = 8.4); ¹³C NMR δ 32.7, 56.4, 56.9, 57.0, 57.1, 103.8, 107.2, 108.5, 115.7, 124.9, 125.1, 128.2, 129.5, 130.1, 131.6, 136.9, 141.1, 149.0, 150.5, 151.2, 152.8, 208.0; HRMS calcd for C₂₁H₁₉NO₇-C₂H₃O: 368.1134; found: 368.1135.

The intermediate compound **22** used in sub-part b was prepared as follows.

30

c. **3,4-Dimethoxy-6-nitrophenyl-trimethylstannane (22).** A mixture of hexamethylditin (2.0 g, 6.1 mmol), compound **16** (1.56 g, 6.0 mmol) and Pd(PPh₃)₄ (163 mg, 0.14 mmol) in toluene (50 mL) was heated to reflux under

nitrogen for 10 h. After cooling, 7 M KF aqueous solution (1 mL) was added with vigorous stirring. The mixture was passed through a celite bed and the filtrate was evaporated to dryness. The residue was chromatographed on 75 g silica gel using hexanes:ethyl acetate (5:1) as eluent. The relevant fractions were
5 pooled and evaporated *in vacuo* to give 1.2 g of compound **22** in 58% yield; mp 115 °C; ¹H NMR δ 0.32 (9H, s), 3.94 (3H, s), 3.99 (3H, s), 7.03 (1H, s), 7.88 (1H, s); ¹³C NMR δ -7.2, 56.7, 107.7, 117.3, 134.0, 146.8, 149.8, 154.1; HRMS calcd for C₁₁H₁₇NO₄Sn-CH₃: 329.9937; found: 329.9939.

10 **Example 3. 2,3-Methylenedioxy-8,9-dimethoxybenzo[i]phenanthridine (6).**

Using a procedure similar to that described in Example 1, except replacing the compound **17** used therein with compound **18**, the title compound
15 was prepared in 60% yield; mp >250 °C; IR (Nujol) 1680; UV (CHCl₃) 285, 360, 380 nm (log ε = 3.01, 2.21, 2.47); ¹H NMR δ 4.10 (3H, s), 4.14 (3H, s), 6.15 (2H, s), 7.28 (1H, s), 7.68 (1H, s), 7.83 (1H, s), 7.97 (1H, d, J = 9.2), 8.16 (1H, s), 8.28 (1H, d, J = 9.2), 9.85 (1H, s); ¹³C NMR δ 56.7, 100.3, 102.1, 102.2, 106.1, 109.2, 118.4, 127.5, 128.9, 131.2, 131.7, 140.8, 145.6, 145.7, 148.4,
20 149.9, 150.4, 151.7, 176.1; HRMS calcd for C₂₀H₁₅NO₄: 333.1001; found: 333.0999.

The intermediate compound **18** was prepared as follows.

25

a. **Ethyl-3,4-(methylenedioxy)dihydrocinnamate (19).** Trimethylsilyl chloride 2.5 mL (18.2 mmol) was added to a solution of 1.5 g (7.7 mmol) of 3,4-(methylenedioxy)dihydrocinnamic acid in 70 mL dry ethanol and this mixture was stirred at room temperature under nitrogen for 12 h. The excess ethanol was
30 evaporated *in vacuo* and the residue obtained was chromatographed on 100 g silica gel using 1:9 mixture respectively of ethyl acetate and hexanes to give a quantitative yield of the ester (**19**) as a colorless liquid; ¹H NMR δ 1.21 (3H, t), 2.60 (2H, t), 2.87 (2H, t), 4.08 (2H, q, J = 14.1, 7.3), 5.90 (2H, s), 6.56-6.69 (3H,

m); ^{13}C NMR δ 14.5, 25.1, 34.2, 60.7, 100.8, 106.9, 121.8, 122.2, 122.5, 145.3, 147.1, 173.2; HRMS calcd for $\text{C}_{12}\text{H}_{14}\text{O}_4$: 222.0892; found: 222.0895.

b. **3,4-(Methylenedioxy)phenethylmethylsulfinylmethyl ketone (20).** The anion of dimethyl sulfoxide was prepared by adding 6.0 mL dry dimethyl sulfoxide to 600 mg sodium hydride and heating the mixture at 70-75 °C for 45 min under nitrogen. This reaction mixture was allowed to cool to room temperature and then transferred to a water bath maintained at 5-10 °C. A solution of compound **19** (1.0 g, 4.54 mmol) in 6.0 mL dry dimethyl sulfoxide was added dropwise, over a period of 15 min, to the dimethyl sulfoxide anion generated previously. The reaction mixture was slowly allowed to come to room temperature and stirred for 2 h. The reaction mixture was poured into 100 mL cold water and acidified to pH 3-4 using 1.2 N hydrochloric acid and extracted five times with 40 mL portions of chloroform. The combined organic layer was washed twice with 100 mL portions of distilled water, dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo* to give quantitative yield of **20** as a low melting buff colored solid. Compound **20** was found to be unstable to column chromatography using silica gel, however, ^1H NMR of the crude compound indicated that it could be used for the synthesis of **21** without further purification; mp = 60-62 °C; ^1H NMR δ 2.55 (3H, s), 2.75-2.82 (4H, m), 3.56-3.76 (2H, q, $J_1 = 13.8$, $J_2 = 34.3$), 5.82 (2H, s), 6.53-6.65 (3H, m); ^{13}C NMR δ 29.3, 41.4, 47.4, 64.4, 101.3, 108.7, 109.3, 121.6, 134.4, 146.4, 148.1, 202.1.

c. **1,2,3,4-Tetrahydro-1-methylthio-6,7-methylenedioxy-2(1H)-naphthalenone (21).** Trifluoroacetic acid (0.3 mL, 3.7 mmol) was dissolved in 25 mL benzene and added to the reaction flask containing 470 mg (1.85 mmol) of compound **20**. The reaction mixture was heated to reflux for 1.5 h. On cooling to room temperature the reaction mixture was transferred to a separating funnel and washed twice using 10 mL portions of a saturated solution of sodium bicarbonate. The benzene layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo* to give a red syrup which was chromatographed over 100 g of silica gel using 1:9 mixture respectively of ethyl acetate and hexanes to give **21** in 60% yield; mp = 52 °C; ^1H NMR δ 2.05 (3H, s), 2.70-3.10 (4H, m), 4.02 (1H, s), 5.85 (1H, s),

6.65 (1H, d, $J=8.1$), 6.72 (1H, d, $J=8.1$); ^{13}C NMR δ 16.3, 21.1, 34.2, 54.1, 101.6, 107.9, 118.5, 123.0, 127.6, 145.1, 147.3, 203.5; HRMS calcd for $\text{C}_{12}\text{H}_{12}\text{O}_3\text{S}$: 236.0507; found: 236.0505.

5 d. **6,7-Methylenedioxy-2-tetralone (9).** A solution of **21** (669 mg, 2.83 mmol) in 10 mL glacial acetic acid was placed in a hydrogenation flask. To this mixture 460 mg of 10% Pd-C was added and the resulting mixture was shaken in a Parr apparatus at 40 psig of hydrogen for 40 h. The reaction mixture was filtered through a celite bed, which was washed thrice with 5 mL portions of glacial acetic acid. The glacial acetic acid was rotaevaporated to give the crude tetralone, **9**. The crude tetralone was then treated with sodium bisulfite to convert it to the more stable bisulfite adduct. Pure tetralone was generated as required from its bisulfite adduct by treatment with 10% sodium carbonate solution followed by extraction with dichloromethane; mp = 91-92 °C (lit¹⁴⁴ = 88-91 °C); IR (Nujol) 1727; ^1H NMR δ 2.51 (2H, t), 2.97 (2H, t), 3.48 (2H, s), 5.92 (2H, s), 6.58 (1H, s), 6.69 (1H, s); ^{13}C NMR δ 21.5, 37.7, 45.1, 101.4, 107.5, 118.5, 121.0, 127.8, 144.2, 146.4, 211.5; Anal. calcd for $\text{C}_{11}\text{H}_{10}\text{O}_3$: C, 69.46, H, 5.30; Found: C, 69.40, H, 5.29.

e. **2-Bromo-6,7-methylenedioxy-1-naphthaldehyde (11).** Using a procedure similar to that described in Example 1, sub-part a, except replacing the compound **8** used therein with Compound **9**, compound **11** was prepared in 96% yield; mp = 165-166 °C; IR (Nujol) 1680; ^1H NMR δ 6.09 (2H, s), 7.05 (1H, s), 7.51 (1H, d, $J=8.7$), 7.63 (1H, d, $J=8.7$), 8.60 (1H, s), 10.68 (1H, s); ^{13}C NMR δ 102.1, 102.3, 104.6, 127.4, 129.5, 129.6, 130.1, 131.1, 134.6, 148.6, 151.7, 195.5; Anal. calcd for $\text{C}_{12}\text{H}_7\text{O}_3\text{Br}$: C, 51.60, H, 2.51; Found: C, 51.98, H, 2.48.

f. **2-Bromo-6,7-methylenedioxy-naphthaldehyde-1-ethylacetal (13).** Using a procedure similar to that described in Example 1, sub-part b, except replacing the compound **10** used therein with compound **11**, compound **13** was prepared in 95% yield; IR (Nujol) 1665, 1617; ^1H NMR δ 4.11-4.18 (2H, m), 4.36-4.43 (2H, m), 6.03 (2H, s), 6.56 (1H, s), 7.05 (1H, s), 7.41-7.48 (2H, m), 7.73 (1H, s); ^{13}C NMR δ 65.6, 101.8, 102.6, 104.8, 106.3, 123.0, 128.0, 129.3, 130.4, 131.1, 131.5, 147.9, 148.6; Anal. calcd for $\text{C}_{14}\text{H}_{11}\text{O}_4\text{Br}$: C, 52.10, H, 3.41; Found: C, 52.52, H, 3.48.

- g. **1-Formyl-6,7-methylenedioxy-naphth-2-yl boronic acid (15).** Acetal 13 (1.4 mmol) was dissolved in 10 mL anhydrous tetrahydrofuran. This solution was stirred under nitrogen at -78°C . A hexanes solution of n-butyllithium (1.2 mL, 2.8 mmol) was added slowly and the reaction mixture was stirred at -78°C for 30 min.
- 5 A pale yellowish brown solution was obtained. To this yellow reaction mixture trimethylborate (0.5 mL, 4.2 mmol) was added and the resulting mixture was stirred at -78°C for 1 h prior to allowing it to come to room temperature. A 5% solution of hydrochloric acid (20 mL) was added to the reaction mixture and stirred for 30 min at room temperature. The tetrahydrofuran was evaporated *in vacuo* and the
- 10 water layer was extracted with dichloromethane. The combined organic layer was washed once with brine, dried and evaporated to give the boronic acid derivative 15, which was used in the subsequent step without further purification.
- h. **2-(3,4-Dimethoxy-6-nitrophenyl)-6,7-methylenedioxy-1-naphthaldehyde (18).** Using a procedure similar to that described in Example 1,
- 15 sub-part d, except replacing the compound 14 used therein with compound 15, compound 18 was prepared in 25% yield; mp = 225°C ; IR (Nujol) 1670, 1515, 1309; ^1H NMR δ 3.92 (3H, s), 4.04 (3H, s), 6.13 (2H, s), 6.74 (1H, s), 7.13 (1H, d, $J = 8.3$), 7.18 (1H, s), 7.77 (1H, s), 7.87 (1H, d, $J = 8.3$), 8.76 (1H, s), 10.14 (1H,
- 20 s); ^{13}C NMR δ 57.0, 57.1, 102.1, 103.1, 104.7, 108.2, 114.9, 125.7, 127.9, 128.8, 129.5, 131.5, 133.6, 141.2, 144.1, 148.6, 149.2, 151.6, 152.9, 193.6.

Example 4. 8,9-Dimethoxy-5-methyl-2,3-methylenedioxybenzo[i]-phenanthridine (7).

25

Using a procedure similar to that described in Example 1, except replacing the compound 17 used therein with compound 26, the title compound was prepared in 63% yield; mp $>250^{\circ}\text{C}$; IR (Nujol) 1685; UV (CHCl_3) 280, 365, 385 nm (log $\epsilon = 2.79, 1.90, 2.03$); ^1H NMR δ 3.36 (3H, s), 4.08 (3H, s), 4.13 (3H, s), 6.15 (2H, s), 7.31 (1H, s), 7.51 (1H, s), 7.80 (1H, s), 7.93 (1H, d, $J = 9.1$), 8.29-8.35 (2H, m); ^{13}C NMR δ 31.7, 56.6, 102.1, 105.8, 106.3, 108.8, 118.5, 119.1, 122.9, 127.9, 130.2, 131.3, 132.7, 137.1, 140.3, 147.3, 148.8, 149.7, 151.7, 155.2; HRMS calcd for $\text{C}_{21}\text{H}_{17}\text{NO}_4$: 347.1158; found: 347.1156.

30

The intermediate compound 26 was prepared as follows.

- a. **1-Aceto-2-bromo-6,7-methylenedioxy-naphthalene (24).** Using a procedure similar to that described in Example 3, sub-part a, except replacing the compound 10 used therein with compound 11, compound 24 was prepared in 90% yield; mp = 138 °C; IR (Nujol) 1695; ¹H NMR δ 2.67 (3H, s), 6.06 (2H, s), 6.89 (1H, s), 7.09 (1H, s), 7.41 (1H, d, *J* = 8.8), 7.56 (1H, d, *J* = 8.8); ¹³C NMR δ 32.4, 101.0, 102.1, 104.9, 113.6, 127.6, 128.4, 129.6, 130.1, 139.8, 148.6, 149.7, 205.2; HRMS calcd for C₁₃H₉O₃Br: 291.9735; found: 291.9730.
- b. **1-Aceto-2-(3,4-dimethoxy-6-nitrophenyl)-6,7-methylenedioxy-naphthalene (26).** Using a procedure similar to that described in Example 3, sub-part b, except replacing the compound 23 used therein with compound 24, compound 26 was prepared in 20% yield; mp = 190-192 °C; IR (Nujol) 1680, 1523, 1300; ¹H NMR δ 2.23 (3H, s), 3.89 (3H, s), 4.01 (3H, s), 6.07 (2H, s), 6.75 (1H, s), 7.06 (1H, d, *J* = 8.4), 7.10 (1H, s), 7.16 (1H, s), 7.66 (2H, m); ¹³C NMR δ 32.6, 56.9, 57.1, 101.7, 102.6, 105.0, 108.4, 115.6, 125.1, 126.0, 128.7, 129.5, 130.8, 131.5, 133.8, 144.5, 149.6, 150.5, 150.7, 152.8, 207.6.

20 **Example 5. 2,3-Dimethoxy-9-benzyloxybenzo[i]phenanthridine (30).**

2-(4-Benzyloxy-6-nitrophenyl)-6,7-dimethoxy-1-naphthaldehyde (100mg, 0.23mmol) was dissolved in glacial acetic acid (15mL) and heated to reflux with zinc dust (163 mg, 2.5mmol) for 3.5 h. Acetic acid was evaporated *in vacuo* and the residue was dissolved in chloroform. The solution was filtered through a celite bed and the filtrate was washed successively with saturated sodium bicarbonate solution and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 50g of silica gel using 1:2 mixture respectively of hexanes and ethyl acetate to give the title compound as a white solid in 56% yield; ¹H NMR(CDCl₃) δ 4.08(3H, s), 4.18(3H, s), 5.29(2H, s), 7.33(1H, s), 7.42(5H, m), 7.52(1H, d, *J*=8.9), 7.72(1H, d, *J*=2.6), 8.02(1H, d, *J*=8.9), 8.17(1H, s), 8.39(1H, d, *J*=8.9), 8.52(1H, d, *J*=8.9), 10.04(1H, s); ¹³C NMR(CDCl₃) δ 56.5,

56.6, 70.8, 102.3, 108.6, 110.9, 112.8, 118.4, 119.6, 120.7, 124.2, 125.8, 127.7,
128.2, 128.6, 129.2, 131.4, 131.7, 137.1, 146.8, 148.6, 150.1, 151.2, 159.5;
HRMS calcd for $C_{26}H_{21}NO_3$: 395.1521, found: 395.1522.

5 The intermediate nitroaldehyde was prepared as follows.

a. **2-Bromo-3,4-dihydro-6,7-dimethoxy-1-naphthaldehyde.**

Dimethylformamide (1.6ml, 20mmol) was added dropwise to a solution of
phosphorus tribromide (1.6ml, 17 mmol) in dry chloroform (25 ml) at 0°C. The
10 mixture was stirred at 0°C for 1 h to give pale yellow suspension. A solution of
6,7-Dimethoxy-2-tetralone (1.0 g, 4.9 mmol) in dry chloroform(20ml) was
added to the yellow suspension and the mixture was heated at reflux for 1 h. The
reaction mixture was cooled to 0°C and saturated aqueous NaHCO₃ solution was
added dropwise until no effervescence was obtained. The resulting mixture was
15 extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered
and evaporated *in vacuo*. The residue was chromatographed over 100g of silica
gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the
bromoaldehyde in 80% yield; ¹H NMR(CDCl₃) δ 2.83(2H, t, J=8.0), 3.88(3H, s),
3.89(3H, s), 6.66(1H, s), 7.71(1H, s), 10.31(1H, s); ¹³C NMR(CDCl₃) δ 28.9,
20 38.5, 56.4, 56.5, 110.0, 111.1, 123.0, 128.0, 132.7, 144.2, 147.7, 149.1, 193.6.

b. **2-Bromo-6,7-dimethoxy-1-naphthaldehyde.** 2-Bromo-3,4-dihydro-6,7-
dimethoxy-1-naphthaldehyde (960mg, 3.23 mmol) and DDQ (880 mg, 3.88mmol)
was refluxed in toluene(45 mL) for 12 h. After cooling to room temperature, the
25 mixture was subjected to filtration through a celite bed and the filtrate was
evaporated to dryness. The residue obtained was chromatographed on 100g silica
gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the
aromatic compound in 95% yield; IR(KBr) 1671; ¹H NMR(CDCl₃) δ 4.00(3H, s),
4.05(3H, s), 7.07(1H, s), 7.54(1H, d, J=8.5), 7.79(1H, d, J=8.5), 8.71(1H, s),
30 10.74(1H, s); ¹³C NMR(CDCl₃) δ 56.3, 56.6, 104.2, 107.0, 126.5, 128.8, 129.4,
129.8, 129.9, 134.3, 150.4, 153.1, 195.9; HRMS calcd for C₁₇H₁₁O₃Br: 293.9891;
found: 293.9896.

c. **4-Bromo-3-nitrophenol.** 4-Bromo-3-nitroanisole (2.32g, 10mmol) was dissolved in 25mL dichloromethane and cooled in an acetone-dry ice bath at -78 °C under nitrogen. A solution of BBr₃ (1.0M in dichloromethane) (25 mL, 25 mmol) was added dropwise. Gradually increased temperature to 20 °C, stirred for 30 h. The reaction mixture was cooled to 0 °C and distilled water (30 mL) was added dropwise. The aqueous layer was extracted with ethyl acetate (30mL x 2) . The combined organic layer was washed successively with saturated NaHCO₃ solution (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 100 g of silica gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the phenol in 70% yield; ¹H NMR(CDCl₃) δ 6.92(1H, dd, J₁=2.9, J₂=8.8), 7.36(1H, d, J=2.9), 7.56(1H, d, J=8.8); ¹³C NMR(CDCl₃) δ 105.2, 113.4, 116.4, 121.4, 136.3, 155.9; HRMS calcd for C₆H₄NO₂Br: 216.9374, found: 216.9375.

d. **5-Benzyloxy-2-bromonitrobenzene.** A solution of 4-Bromo-3-nitrophenol (1.0g, 4.6 mmol) and benzyl bromide (0.82 mL, 7 mmol) in acetonitrile (30 mL) and acetone (15mL) was treated with K₂CO₃ (970mg, 7 mmol). The resulting mixture was heated at reflux under nitrogen for 17 h. The reaction mixture was evaporated *in vacuo* and the residue was dissolved in 40 mL ethyl acetate. The solution was filtered under vacuum then the filtrate was washed successively with distilled water (30mL), 1M HCl solution (30 mL x 3), brine (30mL). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo* . The residue was chromatographed over 100 g of silica gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the benzyl alcohol in 95% yield; ¹H NMR(CDCl₃) δ 5.11(2H, s), 7.02(1H, dd, J₁=2.9, J₂=8.9), 7.41(5H, m), 7.46(1H, d, J=2.9), 7.60(1H, d, J=8.9); ¹³C NMR(CDCl₃) δ 71.4, 105.4, 112.4, 121.1, 128.1, 128.9, 129.1, 129.3, 129.5, 135.8, 136.0, 138.2, 158.7 ; HRMS calcd for C₁₂H₁₀NO₂Br: 306.9844; found: 306.9846.

e. **4- Benzyloxy-2-nitrophenyl-trimethylstannane.** A mixture of hexmethylditin (1.0g, 3 mmol), 5-Benzyloxy-2-bromonitrobenzene (462mg, 1.5mmol) and Pd(PPh₃)₄ (70mg) in anhydrous THF (25ml) was heated to reflux under nitrogen for 18 h. After cooling to room temperature, THF was evaporated and methylene chloride (30ml) was added to the residue. To this mixture, potassium fluoride solution (7M, 2ml) was added dropwise with vigorous stirring. The mixture was passed through a celite bed and the filtrate was washed with brine. The methylene chloride layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 100g of silica gel using 6:1 mixture respectively of hexanes and ethyl acetate to give the stannane in 70% yield; ¹H NMR(CDCl₃) δ 0.32 (9H, s), 5.16(2H, s), 7.24(1H, dd, J₁=2.5, J₂=8.1), 7.42(5H, m), 7.56(1H, d, J=8.1), 7.95(1H, d, J=2.5); ¹³C NMR(CDCl₃) δ -7.3, 70.9, 110.4, 121.8, 128.0, 128.8, 129.2, 130.7, 136.4, 138.2, 154.6, 160.3.

15

f. **2-(4-Benzyloxy-6-nitrophenyl)-6,7-dimethoxy-1-naphthaldehyde.** Pd(PPh₃)₄ (60mg, 0.07mmol) and CuBr (10mg, 0.07mmol) was added to a solution of compound 2-bromo-6,7-dimethoxy-1-naphthaldehyde (204mg, 0.69 mmol) and 4- benzyloxy-2-nitrophenyl-trimethylstannane (320 mg, 0.82 mmol) in THF(20 mL). The resulted mixture was refluxed under nitrogen for 6 h. After cooling to room temperature, THF was evaporated and ethyl acetate (30 mL) was added to the residue. The resulting solution was washed with distilled water (20 mL). The two phases was seperated as much as possible and the aqueous layer was discarded. The remaining was passed through a celite bed. Seperated organic layer was washed with brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 75g of silica gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the nitroaldehyde as light yellow solid in 92% yield; ¹H NMR(CDCl₃) δ 4.05(3H, s), 4.09(3H, s), 5.21(2H, s), 7.12(1H, d, J=8.3), 7.18(1H, s), 7.28(1H, d, J=2.3), 7.30(1H, s), 7.45(5H, m), 7.72(1H, d, J=2.3), 7.88(1H, d, J=8.3), 8.86(1H, s), 10.18(1H, s); ¹³C NMR(CDCl₃) δ 56.3, 56.6, 71.4, 105.2, 107.1, 110.9, 114.1, 120.0, 123.9, 125.8, 126.4, 127.1, 127.4,

30

128.1, 129.0, 129.4, 130.3, 133.2, 134.7, 135.9, 150.3, 150.9, 168.8, 193.9;

HRMS calcd for $C_{26}H_{21}NO_6$: 443.1369, found: 443.1370.

Example 6. 2,3-Dimethoxy-9-aminobenzo[i]phenanthridine (31).

5

2-(4,6-Dinitrophenyl)-6,7-dimethoxy-1-naphthaldehyde (100mg, 0.26mmol) was dissolved in glacial acetic acid (15mL) and heated to reflux with zinc dust (180 mg, 2.7mmol) for 3 h. Acetic acid was evaporated *in vacuo* and the residue was dissolved in chloroform. The solution was filtered through a celite bed and the filtrate was washed successively with saturated sodium bicarbonate solution and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 50g of silica gel using 8:1 mixture respectively of ethyl acetate and methanol to give the title compound as an orange-yellow solid in 15 30% yield; 1H NMR(CD_3OD) δ 3.95(3H, s), 4.04(3H, s), 7.12(1H, dd, $J_1=8.8$, $J_2=2.3$), 7.22(1H, d, $J=2.3$), 7.26(1H, s), 7.86(1H, d, $J=9.0$), 7.98(1H, s), 8.17(1H, d, $J=9.0$), 8.29(1H, d, $J=8.8$), 9.68(1H, s); ^{13}C NMR(CD_3OD) δ 59.3, 59.5, 105.0, 112.4, 112.9, 120.9, 121.4, 122.6, 123.2, 127.7, 129.7, 131.2, 135.7, 136.2, 149.5, 151.3, 153.5, 153.7, 155.1; HRMS calcd for $C_{19}H_{16}N_2O_5$: 304.1212, 20 found: 304.1212.

The intermediate nitro aldehyde was prepared as follows.

a. **2,4-Dinitro-trimethylstannane.** A mixture of hexmethylditin (1.0g, 3.0 mmol), and 2,4-dinitroiodobenzene (588mg, 2.0mmol) and $Pd(PPh_3)_4$ (95mg) in anhydrous THF (25ml) was heated to reflux under nitrogen for 18 h. After cooling to room temperature, THF was evaporated and methylene chloride (30ml) was added to the residue. To this mixture, potassium fluoride solution (7M, 2ml) was added dropwise with vigorous stirring. The mixture was passed 30 through a celite bed and the filtrate was washed with brine. The methylene chloride layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 100g of silica gel using 6:1 mixture respectively of hexanes and ethyl acetate to give the stannane as shining

yellow crystals in 53% yield; ^1H NMR(CDCl_3) δ 0.43(9H, s), 7.93(1H, d, $J=8.0$), 8.42(1H, dd, $J_1=8.0$, $J_2=2.1$), 9.11(1H, d, $J=2.1$); ^{13}C NMR(CDCl_3) δ -6.9, 119.2, 127.2, 139.0, 149.4, 150.0, 154.1; HRMS calcd for $\text{C}_9\text{H}_{12}\text{N}_2\text{O}_4\text{Sn-CH}_3$: 316.9584; found: 316.9584.

5

b. **2-(4,6-Dinitrophenyl)-6,7-dimethoxy-1-naphthaldehyde.** Pd(PPh₃)₄ (60mg, 0.07mmol) and CuBr (10mg, 0.07mmol) was added to a solution of compound 2-Bromo-6,7-dimethoxy-1-naphthaldehyde (186mg, 0.63 mmol) and compound 2,4-dinitrotrimethylstannane (250 mg, 0.76 mmol) in THF(20 mL).

- 10 The resulted mixture was refluxed under nitrogen for 6 h. After cooling to room temperature, THF was evaporated and ethyl acetate (30 mL) was added to the residue. The resulting solution was washed with distilled water (20 mL). The two phases was seperated as much as possible and the aqueous layer was discarded. The remaining was passed through a celite bed. Seperated organic layer was
- 15 washed with brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 75g of silica gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the nitroaldehyde as yellow solid in 95% yield; ^1H NMR(CDCl_3) δ 4.06(3H, s), 4.10(3H, s), 7.10(1H, d, $J=8.3$), 7.22(1H, s), 7.64(1H, d, $J=8.3$), 7.95(1H, d, $J=8.3$), 8.50(1H, dd, $J_1=8.3$, $J_2=2.3$), 8.63(1H, s), 8.96(1H, d, $J=2.3$), 10.30(1H, s); ^{13}C NMR(CDCl_3) δ 56.4, 56.7, 104.3, 107.1, 120.5, 124.5, 126.9, 128.0,
- 20 131.0, 133.4, 134.7, 139.3, 142.2, 148.0, 149.3, 151.0, 153.4, 191.9; HRMS calcd for $\text{C}_{19}\text{H}_{14}\text{N}_2\text{O}_6$: 382.0801, found: 382.0801.

25 **Example 7. 2,3,8,9-Dimethylenedioxybenzo[i]phenanthridine (29).**

- Compound 2-(3,4-methylenedioxy-6-nitophenyl)-6,7-methylenedioxy-1-naphthaldehyde (100mg, 0.30mmol) was dissolved in glacial acetic acid (20mL) and heated to reflux with zinc dust (200mg, 3.2mmol) for 3 h. Acetic acid was
- 30 evaporated *in vacuo* and the residue was dissolved in chloroform. The solution was filtered through a celite bed and the filtrate was washed successively with saturated sodium bicarbonate solution and brine. The organic layer was dried

over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 75g of silica gel using 1:1 mixture respectively of hexanes and ethyl acetate to give the title compound in 40% yield; ¹H NMR(CDCl₃) δ 6.17(2H, s), 6.18(2H, s), 7.31(1H, s), 7.58(1H, s), 7.92(1H, s), 7.96(1H, d, J=9.2), 8.20(1H, s), 8.25(1H, d, J=9.2), 9.88(1H, s); ¹³C NMR(CDCl₃) δ 99.8, 100.4, 102.1, 102.3, 106.2, 107.7, 118.8, 123.9, 127.0, 127.9, 130.9, 131.3, 146.2, 148.3, 149.7, 151.3, 152.0, 152.9, 154.4; HRMS calcd for C₁₈H₁₁NO₂: 317.0688, found: 317.0688.

10 The intermediate nitro aldehyde was prepared as follows.

a. **3-(3,4-Methylenedioxyphenyl) propionyl chloride.** 3-(3,4-Methylenedioxyphenyl) propionic acid (600mg, 3.0mmol) was suspended in methylene chloride (10ml) and catalytic amount of pyridine (1 drop) was added. 15 Thionyl chloride (0.27ml, 3.6mmol) was then added dropwise and the reaction mixture was stirred vigorously under nitrogen at room temperature for 20 h. After reaction was completed(monitored by TLC), reaction mixture was evaporated *in vacuo* to give a quantitative yield of the acid chloride as a yellow oil which was used without further purifications. ¹H NMR(CDCl₃) δ 2.93(2H, t, J=7.3), 3.16(2H, t, J=7.3), 5.94(2H, s), 6.63(1H, d, J=7.7), 6.68(1H, s), 6.73(1H, d, J=7.7); ¹³C NMR(CDCl₃) δ 31.3, 40.3, 101.5, 108.9, 109.2, 121.8, 132.8, 146.9 20 148.3 173.5.

b. **1-[2-(Diazomethylcarbonyl)ethyl]-3,4-methylenedioxybenzene.** To a 25 solution of TMSCHN₃ (3ml, 6mmol, 2M in hexane) in 5 ml THF – acetonitrile (1:1) was added dropwise a solution of compound 3-(3,4-Methylenedioxyphenyl)-propionyl chloride (600mg, 3mmol) in 5 ml THF – acetonitrile (1:1) at 0 °C. The resulted mixture was stirred at 0 °C for 4 h. After reaction was completed, reaction mixture was evaporated *in vacuo* to give the 30 diazo compound as a red viscous oil in 95% yield which was used without further purifications.

c. **6,7-Methylenedioxy-2-tetralone.** To a solution of rhodium(II) acetate in dichloromethane (15 ml) was added dropwise a dichloromethane solution of compound 1-[2-(diazomethylcarbonyl)ethyl]-3,4-methylenedioxybenzene. The resulted mixture was refluxed under nitrogen for 1 h. Then the reaction mixture
5 was evaporated *in vacuo* to give the tetralone as deep yellow crystals in 90% yield which was used without further purifications. mp=91-92 °C; IR(Nujol) 1727; ¹H NMR(CDCl₃) δ 2.52(2H, t, J=6.9), 2.96(2H, t, J=6.9), 3.48(2H, s), 5.93(2H, s), 6.60(1H, s), 6.71(1H, s); ¹³C NMR(CDCl₃) δ 28.7, 38.7, 45.4, 101.4, 108.7, 108.9, 121.7, 126.6, 130.3, 147.0, 210.9; Anal calcd for C₁₁H₁₀O₂:
10 C, 69.46 H, 5.30; found: C, 69.40, H, 5.29.

d. **2-Bromo-3,4-dihydro-6,7-methylenedioxy-1-naphthaldehyde.** Dimethylformamide (0.8ml, 10mmol) was added dropwise to a solution of phosphorus tribromide (0.8ml, 8.5mmol) in dry chloroform (20 ml) at 0 °C.
15 The mixture was stirred at 0 °C for 1 h to give pale yellow suspension. A solution of compound 6,7-methylenedioxy-2-tetralone (500mg, 2.6 mmol) in dry chloroform(20ml) was added to the yellow suspension and the mixture was heated at reflux for 1 h. The reaction mixture was cooled to 0 °C and saturated aqueous NaHCO₃ solution was added dropwise until no effervescence was
20 obtained. The resulting mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo*. The residue was chromatographed over 100g of silica gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the aldehyde in 60% yield; ¹H NMR(CDCl₃) δ 2.80(2H, t, J=7.8), 2.98(2H, t, J=7.8), 5.93(2H, s), 6.64(1H, s), 7.57(1H, s),
25 10.28(1H, s); ¹³C NMR(CDCl₃) δ 29.3, 30.4, 101.6, 107.3, 108.6, 124.0, 129.7, 132.7, 114.0, 146.7, 147.7, 193.2.

e. **2-Bromo-6,7-methylenedioxy-1-naphthaldehyde.** 2-Bromo-3,4-dihydro-6,7-methylenedioxy-1-naphthaldehyde (160mg, 0.57 mmol) and DDQ (
30 154 mg, 0.68mmol) was refluxed in toluene(20 mL) for 12 h. After cooling to room temperature, the mixture was subjected to filtration through a celite bed and the filtrate was evaporated to dryness. The residue obtained was

chromatographed on 75g silica gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the aromatic aldehyde in 90% yield; ^1H NMR(CDCl_3) δ 6.11(2H, s), 7.10(1H, s), 7.53 (1H, d, $J=8.5$), 7.67(1H, d, $J=8.5$), 8.65(1H, s), 10.73(1H, s); ^{13}C NMR (CDCl_3) δ 102.1, 102.3, 104.7, 127.4, 129.5, 129.7, 130.2, 131.2, 134.7, 148.6, 151.7, 195.6; Anal. calcd for $\text{C}_{12}\text{H}_9\text{O}_2\text{Br}$: C, 51.60, H, 2.51 ; found: C, 51.98, H, 2.48.

f. **2-(3,4-Methylenedioxy-6-nitrophenyl)-6,7-methylenedioxy-1-naphthaldehyde.** Pd(PPh₃)₄ (60mg) and CuBr (10mg) was added to a solution of compound 2-Bromo-6,7-methylenedioxy-1-naphthaldehyde (176mg, 0.63 mmol) and compound 3,4- methylenedioxy-6-nitrophenyl-trimethylstannane (251 mg, 0.76 mmol) in THF(20 mL). The resulted mixture was refluxed under nitrogen for 12 h. After cooling to room temperature, THF was evaporated and ethyl acetate (30 mL) was added to the residue. The resulting solution was washed with distilled water (20 mL). The two phases was seperated as much as possible and the aqueous layer was discarded. The remaining was passed through a celite bed. Seperated organic layer was washed with brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo* . The residue was chromatographed over 75g of silica gel using 3:1 mixture respectively of hexanes and ethyl acetate to give the nitroaldehyde in 70% yield; ^1H NMR (CDCl_3) δ 6.12(2H,s), 6.21(2H, s), 6.76(1H, s), 7.09(1H, d, $J=8.4$), 7.18(1H, s), 7.66(1H, s), 7.84(1H, d, $J=8.4$), 8.74(1H, s), 10.19(1H, s); ^{13}C NMR(CDCl_3) δ 102.2, 103.0, 103.8, 104.7, 105.9, 112.2, 124.4, 125.5, 127.7, 128.8, 131.4, 131.6, 133.7, 143.6, 148.6, 151.7, 156.3, 163.5, 193.3.

25

The intermediate stannane used in sub-part f was prepared as follows.

g. **3,4- Methylenedioxy-2-bromonitrobenzene.** 3,4-Methylenedioxy-bromobenzene (5g, 23mmol) was slowly added to a stired solution of 35ml concentrated nitric acid and 105ml glacial acetic acid maintained at 10 °C. The reaction mixture was stired at 15 °C for 1 h and then diluted with 200ml ice cold water. The resulting mixture was extracted twice with 200 ml portions of ether.

The combined organic phase was dried and evaporated *in vacuo* to give the crude product. The crude product was recrystallized from ethanol to give bright yellow needle shaped crystals of the nitro compound in 90% yield; mp 87-89 °C; IR(KBr) 1528, 1333; ¹H NMR (CDCl₃) δ 6.14(2H,s), 7.12(1H, s), 7.45(1H, s);
5 ¹³C NMR(CDCl₃) δ 104.0, 107.0, 109.0, 114.3, 146.2, 148.0, 152.1; HRMS calcd for C₇H₅BrNO₂ : 244.9323; found: 244.9324.

h. **3,4- Methyleneedioxy-6-nitrophenyl-trimethylstannane.** A mixture of hexmethylditin (3g, 10mmol), the compound from sub-part g (1.6g, 6.9mmol)
10 and Pd(PPh₃)₄ (200mg) in anhydrous THF (30ml) was heated to reflux under nitrogen for 7 h. After cooling to room temperature, THF was evaporated and methylene chloride (30ml) was added to the residue. To this mixture, potassium fluoride solution (7M, 2ml) was added dropwise with vigorous stirring. The mixture was passed through a celite bed and the filtrate was washed with brine.
15 The methylene chloride layer was dried over anhydrous sodium sulfate, filtered and evaporated *in vacuo* . The residue was chromatographed over 100g of silica gel using 6:1 mixture respectively of hexanes and ethyl acetate to give the stannane in 60% yield; ¹H NMR(CDCl₃) δ 0.32(9H,s), 6.12(2H, s), 7.03(1H, s), 7.80(1H, s); ¹³C NMR(CDCl₃) δ -6.9, 103.3, 105.9, 114.7, 137.2, 147.9, 149.4,
20 153.4; HRMS calcd for C₁₀H₁₁NO₂Sn-CH₃ : 315.9632, found: 315.9638 .

Example 8. 2,8,9-Trimethoxybenzo[*i*]phenathridine.

A mixture of 2-(3,4-dimethoxyphenyl)-6-methoxy-1-naphthaldehyde (46
25 mg, 0.12 mmol) in acetic acid (4 ml) and zinc dust (100 mg, 1.5 mmol) was heated to reflux for 4 h. Acetic acid was evaporated *in vacuo* and the residue extracted with chloroform. The chloroform solution was filtered through a celite bed. The filtrate was washed successively with saturated sodium bicarbonate solution and brine and evaporated to dryness. The residue obtained was
30 chromatographed on 75 g silica using a 1:1 mixture of hexanes:ethyl acetate as eluent to give the title compound (27 mg, 68%): mp 207-209°C; IR (KBr) 1620, 1487, 1215; ¹H NMR CDCl₃) δ 4.00 (3H, s) 4.09 (3H, s), 4.14, (3H, s), 7.33

- (1H, d, $J = 2.6$), 7.40 (1H, dd, $J = 9.2, 2.6$), 7.62 (1H, s), 7.85 (1H, s), 8.03 (1H, d, $J = 9.0$), 8.41 (1H, d, $J = 9.0$), 8.77 (1H, d, $J = 9.2$), 9.99 (1H, s); ^{13}C NMR (CDCl_3) δ 55.3, 56.6, 101.9, 108.8, 110.0, 119.6, 120.8, 121.7, 124.0, 125.2, 130.4, 131.3, 133.6, 141.8, 145.9, 150.3, 151.5, 158.8; HRMS calcd for $\text{C}_{20}\text{H}_{17}\text{NO}_4 + \text{H}$: 320.1287; found 320.1288.

The intermediate nitro aldehyde was prepared as follows.

- a. **2-(3,4-Dimethoxy-6-nitrophenyl)-6-methoxy-1-naphthaldehyde.**
- 10 Using a procedure similar to that described in Example 7, sub-part f, except replacing the naphthyl bromide and the stannane used therein with the requisite compounds, the nitroaldehyde was prepared; mp 158-160 °C; IR (KBr) 1677, 1518, 1328; ^1H NMR (CDCl_3) δ 3.92 (3H, s), 3.97 (3H, s), 4.05 (3H, s), 6.74 (1H, s), 7.20 (1H, d, $J = 2.7$), 7.25 (1H, d, $J = 8.4$), 7.35 (1H, dd, $J = 9.2, 2.7$), 7.77 (1H, s), 7.94 (1H, d, $J = 8.4$), 9.15 (1H, d, $J = 9.2$), 10.20 (1H, s); ^{13}C NMR (CDCl_3) δ 55.8, 57.1, 107.0, 108.3, 115.0, 122., 126.4, 127.7, 127.9, 128.7, 129.4, 133.5, 135.5, 141.2, 143.0, 149.3, 153.0, 158.7, 193.6; HRMS calcd for $\text{C}_{20}\text{H}_{17}\text{NO}_6 + \text{H}$: 368.1134; found 367.1129.
- 15
- 20 **Example 9. 2,3,8-Trimethoxybenzo[*i*]phenanthridine.**

- A mixture of 2-(4-methoxy-6-nitrophenyl)-6,7-dimethoxy-1-naphthaldehyde (30 mg, 0.81 mmol) in acetic acid (3 ml) and zinc dust (100 mg, 1.5 mmol) was heated to reflux for 3 hours. Acetic acid was evaporated *in vacuo* and the residue extracted with chloroform. The chloroform solution was filtered through a celite bed. The filtrate was washed successively with saturated sodium bicarbonate solution and brine and evaporated to dryness. The residue obtained was chromatographed on 75 g silica using a 1:1 mixture of hexanes:ethyl acetate as eluent to give the title compound (20 mg, 77%); IR (KBr) 1615, 1518, 1272; ^1H NMR (CDCl_3) δ 4.02 (3H, s), 4.08 (3H, s), 4.18 (3H, s), 7.33 (1H, s), 7.37 (1H, dd, $J = 9.1, 2.6$ Hz), 7.54 (1H, d, $J = 2.6$), 8.05 (1H, d, $J = 8.7$), 8.42 (1H, d, $J = 8.7$), 8.56 (1H, d, $J = 9.1$), 10.05 (1H, s); ^{13}C NMR δ 56.1, 56.5, 56.6, 102.2,
- 25
- 30

108.6, 109.5, 119.0, 119.2, 119.3, 120.6, 124.1, 125.8, 127.6, 131.4, 131.7, 146.7, 148.4, 150.1, 151.1, 160.3.; HRMS calcd for $C_{20}H_{17}NO_3$; 319.1208; found 319.1209.

5 The intermediate nitroaldehyde was prepared as follows.

a. **2-(4-Methoxy-6-nitrophenyl)-6,7-dimethoxy-1-naphthaldehyde (23a).**

Using a procedure similar to that described in Example 7, sub-part f, except replacing the naphthyl bromide and the stannane used therein with the requisite
10 compounds, the nitroaldehyde was prepared; mp 200-202 °C; IR (KBr) 1672, 1523, 1256; 1H NMR ($CDCl_3$) δ 3.96 (3H, s) 4.04 (3H, s), 4.09 (3H, s), 7.14 (1H, D, $J = 8.1$), 7.18 (1H, s), 7.20 (1H, s), 7.20 (1H, dd, $J = 8.3, 2.6$), 7.32 (1H, d, $J = 8.3$), 7.83 (1H, d, $J = 2.9$), 7.90 (1H, d, $J = 8.1$), 8.87 (1H, s), 10.17 (1H, s); ^{13}C NMR ($CDCl_3$) δ 56.3, 56.6, 106.2, 107.0, 109.8, 119.4, 1125.9, 126.8, 127.5,
15 130.3, 133.2, 134.7, 143.2, 149.8, 150.4, 153.1, 160.4, 194.0; HRMS calcd for $C_{20}H_{17}NO_6$; 367.1056; found 367.1050.

Example 10. 2,3-Dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine.

A mixture of 2-(3,4-methylenedioxy-6-nitrophenyl)-6,7-dimethoxy-1-
20 naphthaldehyde (46 mg, 0.12 mmol) in acetic acid (3 mL) and zinc dust (100 mg, 1.5 mmol) was heated to reflux for 3 hours. Acetic acid was evaporated *in vacuo* and the residue extracted with chloroform. The chloroform solution was filtered through a celite bed. The filtrate was washed successively with saturated sodium bicarbonate solution and brine and evaporated to dryness. The residue
25 obtained was chromatographed on 75 g silica using a 1:1 mixture of hexanes:ethyl acetate as eluent to give the title compound (32 mg, 80%); mp 171-171°C IR (KBr) 1610, 1461, 1277; 1H NMR ($CDCl_3$) δ 4.06 (3H, s), 4.15 (3H, s), 6.15 (2H, s) 7.27 (1H, s), 7.54 (1H, s), 7.85 (1H, s), 7.94 (1H, d, $J = 8.7$), 8.09 (1H, s), 8.15 (1H, d, $J = 8.7$), 9.88 (1H, s); ^{13}C NMR ($CDCl_3$) δ 56.4, 56.6,
30 99.7, 102.3, 102.4, 107.7, 108.5, 118.5, 21.0, 121.2, 125.6, 127.7, 130.8, 131.2, 142.8, 145.9, 148.8, 149.7, 150.1; HRMS calcd for $C_{20}H_{14}NO_4 + H$; 334.1079.

The intermediate nitroaldehyde was prepared as follows.

- a. **2-(3,4-Methylenedioxy-6-nitrophenyl)-6,7-dimethoxy-1-naphthaldehyde.** Using a procedure similar to that described in Example 7, sub-part f, except replacing the naphthyl bromide and the stannane used therein with the requisite compounds, the nitroaldehyde was prepared; mp 223-225 °C; IR (KBr) 1677, 1502, 1256; ¹H NMR (CDCl₃) δ (3H, s), 4.09 (3H, s), 6.21 (2H, s), 6.78 (1H, s), 7.13 (1H, d, *J* = 8.4), 7.18 (1H, s), 7.66 (1H, s), 7.91 (1H, d, *J* = 8.4), 8.84 (1H, s), 10.22 (1H, s); ¹³C NMR (CDCl₃) δ 56.3, 56.6, 103.9, 105.2, 107.1, 112.3, 125.4, 127.0, 127.5, 130.4, 131.6, 133.3, 143.8, 148.5, 150.1, 151.7, 153.1, 193.6; HRMS calcd for C₂₀H₁₅NO₇+H: 382.0927; found 382.0927

- For sub-part a of Examples 8-10, the requisite intermediate naphthyl bromide can be prepared from commercially available starting materials using a sequence similar to that described in Example 7, sub-parts a-d; and the requisite intermediate stannane can be prepared from commercially available starting materials using a sequence similar to that described in Example 7, sub-parts g and h.

20

Example 11. The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I ('Compound X'), for therapeutic or prophylactic use in humans.

- | | | |
|----|----------------------------|------------------|
| 25 | (i) <u>Tablet 1</u> | <u>mg/tablet</u> |
| | 'Compound X' | 100.0 |
| | Lactose | 77.5 |
| | Povidone | 15.0 |
| | Croscarmellose sodium | 12.0 |
| 30 | Microcrystalline cellulose | 92.5 |
| | Magnesium stearate | 3.0 |
| | | 300.0 |

45

	(ii) <u>Tablet 2</u>	<u>mg/tablet</u>
	'Compound X'	20.0
	Microcrystalline cellulose	410.0
	Starch	50.0
5	Sodium starch glycolate	15.0
	Magnesium stearate	<u>5.0</u>
		500.0
	(iii) <u>Capsule</u>	<u>mg/capsule</u>
10	'Compound X'	10.0
	Colloidal silicon dioxide	1.5
	Lactose	465.5
	Pregelatinized starch	120.0
	Magnesium stearate	<u>3.0</u>
15		600.0
	(iv) <u>Injection 1 (1 mg/ml)</u>	<u>mg/ml</u>
	'Compound X' (free acid form)	1.0
	Dibasic sodium phosphate	12.0
20	Monobasic sodium phosphate	0.7
	Sodium chloride	4.5
	1.0 N Sodium hydroxide solution	
	(pH adjustment to 7.0-7.5)	q.s.
	Water for injection	q.s. ad 1 mL
25	(v) <u>Injection 2 (10 mg/ml)</u>	<u>mg/ml</u>
	'Compound X' (free acid form)	10.0
	Monobasic sodium phosphate	0.3
	Dibasic sodium phosphate	1.1
30	Polyethylene glycol 400	200.0
	0.1 N Sodium hydroxide solution	
	(pH adjustment to 7.0-7.5)	q.s.
	Water for injection	q.s. ad 1 mL
35	(vi) <u>Aerosol</u>	<u>mg/can</u>
	'Compound X'	20.0
	Oleic acid	10.0
	Trichloromonofluoromethane	5,000.0
	Dichlorodifluoromethane	10,000.0
40	Dichlorotetrafluoroethane	5,000.0

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art.


45

All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred

embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

What is claimed is:

1. A compound of formula I:



(I)

wherein

R_1 , R_2 and R_3 are each individually hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_1 and R_2 taken together are methylenedioxy and R_3 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_2 and R_3 taken together are methylenedioxy and R_1 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo;

R_4 is oxy, (C_1-C_6) alkyl, or is absent;

R_5 is hydrogen, hydroxy, or (C_1-C_6) alkyl;

R_6 , R_7 and R_8 are each individually hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_6 and R_7 taken together are methylenedioxy and R_8 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_7 and R_8 taken together are methylenedioxy and R_6 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $C(=O)R_k$, $COOR_k$, OR_m , or halo;

each bond represented by ---- is individually present or absent;

X is $C(R_a)(R_b)$ or NR_c ;

Y is $C(R_d)(R_e)$ or NR_f ;

if present, R_a and R_b are each independently hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ---- is

absent; or R_a is hydrogen or (C_1-C_6) alkyl and R_b is absent if the bond between the 11- and 12-positions represented by ----- is present;

if present, R_c and R_f are each independently hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_c and R_f are each independently (C_1-C_6) alkyl or absent if the bond between the 11- and 12-positions represented by ----- is present;

if present, R_d and R_e are each independently hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ----- is absent; or R_d is hydrogen or (C_1-C_6) alkyl and R_e is absent if the bond between the 11- and 12-positions represented by ----- is present;

each R_g and R_h is independently hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, (C_1-C_6) alkanoyl, aryl, aryl (C_1-C_6) alkyl, aryloxy, or aryl (C_1-C_6) alkoxy; or R_g and R_h together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, or thiomorpholino;

each R_k is independently hydrogen, or (C_1-C_6) alkyl; and

each R_m is independently (C_1-C_6) alkanoyl, aryl, or aryl (C_1-C_6) alkyl;

wherein any (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, or (C_1-C_6) alkoxy of R^1 , R^2 , R^3 , R^6 , R^7 , R^8 , or R_k is optionally substituted on carbon with 1, 2, or 3 substituents independently selected from hydroxy, halo, NR_nR_p , (C_3-C_6) cycloalkyl, or (C_1-C_6) alkoxy; wherein each R_n and R_p is independently hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, or (C_1-C_6) alkanoyl; or R_n and R_p together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, or thiomorpholino;

wherein any aryl is optionally be substituted with 1, 2, or 3 substituents independently selected from hydroxy, halo, nitro, trifluoromethyl, trifluoromethoxy, carboxy, amino, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, and (C_1-C_6) alkoxy;

provided that at least one of R_2 and R_8 is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro; or at least one of R_2 and R_8 forms part of a methylenedioxy; and

provided that R_1-R_3 and R_6-R_8 are not all hydrogen;

or a pharmaceutically acceptable salt thereof.

2. The compound of formula (I) as claimed in claim 1 wherein:

R_1 , R_2 and R_3 are each individually hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_1 and R_2 taken together are methylenedioxy and R_3 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_2 and R_3 taken together are methylenedioxy and R_1 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo;

R_4 is oxy, (C_1-C_6) alkyl, or is absent;

R_5 is hydrogen, hydroxy, or (C_1-C_6) alkyl;

R_6 , R_7 and R_8 are each individually hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_6 and R_7 taken together are methylenedioxy and R_8 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo; or R_7 and R_8 taken together are methylenedioxy and R_6 is hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, nitro, hydroxy, NR_gR_h , $COOR_k$, OR_m , or halo;

each bond represented by ---- is individually present or absent;

X is $C(R_a)(R_b)$ or NR_c ;

Y is $C(R_d)(R_e)$ or NR_f ;

if present, R_a and R_b are each independently hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ---- is absent; or R_a is hydrogen or (C_1-C_6) alkyl and R_b is absent if the bond between the 11- and 12-positions represented by ---- is present;

if present, R_c and R_f are each independently hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ---- is absent; or R_c and R_f are each independently (C_1-C_6) alkyl or absent if the bond between the 11- and 12-positions represented by ---- is present;

if present, R_d and R_e are each independently hydrogen or (C_1-C_6) alkyl if the bond between the 11- and 12-positions represented by ---- is absent; or R_d is hydrogen or (C_1-C_6) alkyl and R_e is absent if the bond between the 11- and 12-positions represented by ---- is present;

each R_g and R_h is independently hydrogen, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_6) alkoxy, (C_1-C_6) alkanoyl, aryl, aryl (C_1-C_6) alkyl, aryloxy, or aryl (C_1-C_6) alkoxy; or R_g and R_h together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, or thiomorpholino;

each R_k is independently hydrogen, or (C_1-C_6) alkyl; and

each R_m is independently (C_1-C_6) alkanoyl, aryl, or aryl (C_1-C_6) alkyl;

wherein any aryl may optionally be substituted with 1, 2, or 3 substituents independently selected from hydroxy, halo, nitro, trifluoromethyl, trifluoromethoxy, carboxy, amino, (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, or (C_1-C_6) alkoxy;


provided that at least one of R_2 and R_8 is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro; or at least one of R_2 and R_8 forms part of a methylenedioxy; and

provided that R_1-R_3 and R_6-R_8 are not all hydrogen;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 wherein R_3 is hydrogen.
4. The compound of claim 1 wherein R_4 is absent and the bond between the 5- and 6-positions represented by ----- is present.
5. The compound of claim 1 wherein R_4 is (C_1-C_6) alkyl.
6. The compound of claim 1 wherein R_5 is methyl or hydrogen.
7. The compound of claim 1 wherein R_1 , R_2 and R_3 are each individually hydrogen, or (C_1-C_6) alkoxy; or R_1 and R_2 taken together are methylenedioxy and R_3 is hydrogen or (C_1-C_6) alkoxy.
8. The compound of claim 1 wherein R_7 or R_8 is (C_1-C_6) alkoxy; or R_7 and R_8 taken together are methylenedioxy.


9. The compound of claim 1 wherein R_7 and R_8 taken together are methylenedioxy.
10. The compound of claim 1 wherein R_2 is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro.
11. The compound of claim 1 wherein R_8 is hydrogen, methyl, nitro, hydroxy, amino, fluoro or chloro.
12. The compound of claim 1 wherein the bonds represented by ----- are both present.
13. The compound of formula (I) as claimed in of claim 1 which is a compound of formula III:



or a pharmaceutically acceptable salt thereof.


14. The compound of formula (I) as claimed in of claim 1 which is a compound of formula IV:

52



or a pharmaceutically acceptable salt thereof.

15. The compound of formula (I) as claimed in of claim 1 which is a compound of formula (V):




or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 wherein wherein R_1 is (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or R_1 and R_2 taken together are methylenedioxy.


17. The compound of claim 1 wherein R_2 is (C_1-C_6) alkoxy, nitro, hydroxy, or halo; or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 wherein R_3 is (C₁-C₆)alkoxy, nitro, hydroxy, or halo; or R_2 and R_3 taken together are methylenedioxy.
19. The compound of claim 1 wherein R_8 is (C₁-C₆)alkoxy, nitro, hydroxy or halo; or R_7 and R_8 taken together are methylenedioxy.
20. The compound of claim 1 wherein R_7 is (C₁-C₆)alkoxy, nitro, hydroxy, or halo.
21. The compound of claim 1 wherein R_6 is (C₁-C₆)alkoxy, nitro, hydroxy, or halo; or R_6 and R_7 taken together are methylenedioxy.
22. The compound of claim 1 which is 2,3-methylenedioxy-8,9-dimethoxybenzo[i]phenanthridine; or a pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition comprising an effective amount of a compound of claim 1, in combination with a pharmaceutically acceptable diluent or carrier.
24. A method of inhibiting cancer cell growth, comprising administering to a mammal afflicted with cancer, an amount of a compound of claim 1, effective to inhibit the growth of said cancer cells.
25. A method comprising inhibiting cancer cell growth by contacting said cancer cell *in vitro* or *in vivo* with an amount of a compound of claim 1, effective to inhibit the growth of said cancer cell.
26. A compound of claim 1 for use in medical therapy.
27. The compound of claim 23 wherein the therapy is treating cancer.
28. The use of a compound of claim 1 for the manufacture of a medicament useful for the treatment of cancer.


Figure 1




4




5




6



7



27



28


Figure 2

Figure 3




Figure 4




Figure 5




Figure 6





Figure 7



INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/US 98/26292

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D215/26 C07D491/04 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	N. ARUMAGAM ET. AL.: "Synthesis of 7,8-Benzophenanthridines." INDIAN JOURNAL OF CHEMISTRY, vol. 12, no. 7, July 1974, pages 664-7, XP002099086 see page 665, compound nos. XXXIV, XXXV and XXXVI ---	1-4,8, 10-13, 15,20
X	S. V. KESSAR ET. AL. : "New Routes to Condensed Polynuclear Compounds Part X. Synthesis of Some Benzo[1]phenanthridines Through Benzyne Cyclisation." INDIAN JOURNAL OF CHEMISTRY, vol. 11, no. 7, July 1973, page 624-7 XP002099087 see Page 624, compounds VIIb, VIIC, Vb, Vc, Vd and Ve --- -/--	1-4,7,8, 10-12, 15,17, 20,21,23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 April 1999

Date of mailing of the international search report

19.05.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/26292

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	K. W. GOPINATH ET. AL.: "Synthesis of Some 1,2 and 7,8-Benzophenanthridines." JOURNAL OF THE CHEMICAL SOCIETY, vol. 1958, 1958, pages 504-9, XP002099088 see page 505, compounds III and IIIa ----	1-4,6-9, 12, 15-17, 19,20
X	S. V. KESSAR ET. AL.: "Azasteroids. Part VII. Synthesis of 7-Hydroxy-2-methoxy-7,8,9,10-tetrahydrobenzo[1,2-b:4,5-b']phenanthridine." JOURNAL OF THE CHEMICAL SOCIETY, C, no. 2, 1971, pages 259-61, XP002099089 see page 260, compound no. IX. ----	1-4,6-8, 10,12, 15,20
Y	WO 97 29106 A (RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY) 14 August 1997 see claims; examples ----	1-28
Y	GB 2 108 955 A (QUATNUM EMPRESA NACIONAL DE QUINICA ORGANICA SARL) 1 October 1981 see claims; examples ----	1-28
Y	US 3 912 740 A (ZEE-CHENG ET. AL.) 14 October 1975 see column 1, line 1 - column 2, line 45; claims; examples -----	1-28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/26292

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 24 and 25 are drawn to a method of treatment of the human body by therapy (Rule 39.1(iv) PCT, the search has been carried out based on the alleged effects of the compounds and compositions.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. onal Application No

PCT/US 98/26292

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9729106 A	14-08-1997	AU 2115597 A	28-08-1997
		CA 2241551 A	14-08-1997
		CZ 9802544 A	16-12-1998
		EP 0888346 A	07-01-1999
		NO 983669 A	23-09-1998
		PL 328402 A	18-01-1999
GB 2108955 A	25-05-1983	PT 73763 A	01-11-1981
		BR 8205780 A	06-09-1983
		DE 3236455 A	05-05-1983
		IN 155552 A	16-02-1985
		NL 8203839 A	02-05-1983
US 3912740 A	14-10-1975	US 4014885 A	29-03-1977